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Abstract 
Background: Breast cancer survivors confront ongoing symptoms following diagnosis and 
treatment.  Studies examining the relationship between biomarkers and symptoms are scarce.  
Purpose: To explore symptom occurrence and severity as reported by breast cancer survivors 
and their relationship to the BDNF Val66Met SNP (a biomarker), daily activities, quality of life 
and other selected subject characteristics and health variables.  In addition, self-care methods 
used by survivors to alleviate symptoms and perceptions of the methods’ usefulness were 
considered.  
Methods: Breast cancer survivors (6 months or more post-treatment) were invited by a coalition 
from a Mid-Atlantic state to participate in an online survey in Phase 1 (N = 195).  The survey 
results provided the basis for a purposive sub-sampling.  In Phase 2, two groups were identified 
from their scores on the Therapy-Related Symptoms Checklist (TRSC; low-scoring [≤ 14, n = 
26] and high-scoring [≥ 23, n = 25]) for BDNF genotyping (by the Taqman probe assay) and 
exploration of self-care.  All self-report tools have good psychometric properties: the TRSC, 
Daily Activities Rating (DAR), Health-Related Quality of Life-Linear Analogue Scale 
Assessment (HRQOL-LASA), and Symptom Alleviation: Self-Care Methods (SA: SCM). 
Fisher’s exact test, logistic and multiple regression, and descriptive and content analyses were 
conducted.   
Findings: (a) The presence of the BDNF Val66Met SNP biomarker was related to lower 
symptom scores, but effect size was small and the relationship did not persist when controlling 
for confounders; (b) TRSC scores were not impacted by time since completion of treatment; (c) 
high total scores on the TRSC (high symptom occurrence and severity) were significantly related 
to high scores on the DAR (difficulty with activities of daily life) and to lower quality of life on 
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the HRQOL-LASA; (d) the odds of a low TRSC score increased with increased education and 
increased age, and diminished if treatment included chemotherapy; (e) the self-care method used 
most commonly was diet/nutrition/lifestyle; the least common was 
herbs/vitamins/complementary therapy, and the methods that were used were perceived as 
effective. 
Clinical Implications and Need for Further Research: Beginning evidence that the BDNF 
Val66Met SNP may have a protective effect for ongoing symptoms in breast cancer survivors. 
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Chapter I 
Introduction 
Breast cancer is the second leading cause of cancer death in women in the United States 
(American Cancer Society, 2007).  One out of eight women will be diagnosed with breast cancer 
in her lifetime; thus, millions of women are living with this disease and the sequelae of 
treatment.  Ongoing symptoms are a considerable problem for breast cancer survivors.  Little 
information is available about possible objective physiological markers that might predict the 
occurrence and severity of these symptoms.  To date, researchers have not investigated the 
impact of brain-derived neurotrophic factor (BDNF) in breast cancer survivors.  Low levels of 
BDNF have been associated with reactive oxygen species (ROS) that result in oxidative stress 
leading to cell death (apoptosis) processes that have been linked to a variety of symptoms (Kim, 
Barsevick, & Tulman, 2009).  The presence of a biological indicator, such as the BDNF 
Val66Met single nucleotide polymorphism (SNP), could be predictive of symptoms that would 
facilitate targeting effective nursing care to specific at-risk individuals or groups.  This would be 
an important step toward improved care for millions of women suffering from the effects of 
breast cancer.  For example, a recently published pilot intervention study with 20 newly 
diagnosed cancer patients, mostly females with breast cancer, yielded some preliminary evidence 
in support of an educational intervention in decreasing symptom occurrence and severity (P. D. 
Williams, Williams, LaFaver-Rolling, Johnson, & Williams, 2011d). 
The original plan was to conduct this study in one Mid-Atlantic state having one of the 
highest incidences of breast cancer in the United States, with 139.2 cases per 100,000 people 
(American Cancer Society, 2007).  Due to a need for further recruitment of subjects, the study 
was expanded to include breast cancer survivors in neighboring states.   
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In one study of breast cancer survivors, Ferrans (1994) emphasized the role of nursing in 
managing symptoms: “To help alleviate these problems, nurses first need to find out what the 
problems are and who is suffering from them.  This sort of problem identification should become 
a routine part of follow-up care for survivors of cancer” (p. 1650).  Women who do not have the 
support they need often find that a nurse acting as an understanding confidant may be a critical 
element in their cancer-related quality of life (Halyard & Ferrans, 2008). 
Documentation of symptoms in a survivorship care plan has recently begun to appear in 
the literature.  Oncology nurses play a key role in a developing model of survivorship care 
planning for patients with breast cancer (Miller, 2008).  There are increasing numbers of people 
being successfully treated for cancer, and there are an estimated 11.4 million cancer survivors in 
the United States, with 23% of those survivors (2.6 million) being female survivors of breast 
cancer (National Cancer Institute, 2006).  Doyle (2008) indicated that millions of women 
globally are survivors of breast cancer.  For example, 87% of the women diagnosed with breast 
cancer can expect to be alive five years later (University of Texas, 2009).  In view of these facts, 
the need for a preliminary study to explore the linkage between BDNF and symptom occurrence 
and severity to allow for a more personalized approach to nursing for breast cancer patients is 
deemed to be a timely and important endeavor. 
Societal, Organizational, and Governmental Goals 
 The American College of Surgeons Commission on Cancer has added survivorship care 
as a new standard for accreditation beginning in 2012 (Commission on Cancer, 2011).  One of 
the seven Oncology Nursing Society (ONS; 2008) research priorities for 2009-2013 is quality of 
life.  Goals from a national breast cancer research agenda published in 1998 by prominent 
members of the scientific, medical, advocacy, and industrial communities organized by the 
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National Cancer Institute (NCI) recommended a renewed focus on psychosocial factors and 
patient outcomes across a continuum of ages and race/ethnicity groups (American Cancer 
Society, 2007).  The American Society of Clinical Oncology (ASCO) has considered quality of 
life issues, such as symptom management, second in importance only to survival as a research 
outcome for nearly two decades (Halyard & Ferrans, 2008). This study is particularly timely due 
to the American Academy of Nursing's identification of nurse sensitive outcomes, which has put 
improvement in self-care, symptom management, and quality of life in the forefront of nursing 
initiatives (Richard & Shea, 2011).   
Background  
 The most recent Oncology Nursing Society statement on the scope and standard of 
oncology nursing practice refers to the process of care as being based on a “continuous healing 
relationship” (Boyle, Bruce, Iwamoto, & Summers, 2004,  p. 3).  Evidence-based symptom 
management and skilled assessments are emphasized in this publication.  This study builds on a 
research program of symptom assessment and management by P. D. Williams and colleagues, 
described in the next chapter, and provides further development of evidence-based practice in 
symptom assessment and management. 
Nursing is a key discipline assisting cancer survivors with ongoing symptoms.  Better 
understanding of symptoms and self-care in breast cancer survivors served by a state coalition 
may provide information that could be applied to oncology nursing and the shaping of health 
care in the United States and beyond.  There currently are no reliable, objective markers to 
indicate which breast cancer patients will continue to have debilitating symptoms after the 
conclusion of their initial treatment regime.  BDNF is emerging as a possible indicator of 
resiliency (Krueger et al., 2011).  Low levels of BDNF production have been related to the 
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BDNF Val66Met SNP.  Based on a survey of the literature, it is possible that such lowered levels 
of BDNF production could be indicative of increased symptom burden.  This preliminary 
feasibility study provides groundwork on which further investigations with cancer survivors 
could be based.  Knowledge of which individuals are positive for the BDNF Val66Met SNP 
could allow nurses to proactively schedule follow-up appointments for at-risk patients, as well as 
tailor and target nursing interventions appropriately. 
Aims and Research Questions 
The primary aim of the study was to examine the relationship between self-reported 
symptom occurrence and severity, as measured by the Therapy-Related Symptom Checklist 
(TRSC) total scores, and the presence or absence of the BDNF Val66Met SNP in breast cancer 
survivors.  Secondary aims were investigated using three additional self-reported measures: 
Daily Activities Rating Scale (DARS), Health-Related Quality of Life - Linear Analogue Self 
Assessment (HRQOL-LASA), and the Symptom Alleviation: Self-Care Methods (SA: SCM) 
scale, as well as selected demographic and other variables (age, ethnicity, education, treatment 
method, and time since treatment).  
Primary Research Question  
Is there a significant relationship between symptom occurrence and severity in breast cancer 
survivors and the presence or absence of the BDNF Val66Met SNP?  
Secondary Research Questions 
1. What are the occurrence and severity of symptoms among breast cancer survivors as 
    reported on the TRSC after the completion of their cancer therapy regimen?  
2. Are there significant relationships among symptom occurrence and severity, daily       
      activities ratings, and health-related quality of life and selected demographic and other    
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      variables (age, ethnicity, education, treatment method, and time since treatment)?  
3. What self-care methods are used by survivors to alleviate symptoms, and what are the 
survivors’ perceptions of the usefulness of these self-care methods?  
Design Overview 
This study had a cross-sectional design with two phases.  Phase 1 enabled participant 
selection for Phase 2.  Phase 2 addressed the primary study RQ.  The purposive Phase 2 
subsample (n = 51) addressed the BDNF Val66Met SNP as a genetic indicator of cancer 
symptoms, using two groups based on the Therapy-Related Symptom Checklist (TRSC) scores 
(low ≤ 14, n = 25; high ≥ 23, n = 26).  The self-report tools have had good psychometric 
properties in previous uses, and the results from this study will be discussed in later chapters.  
Conceptual Framework 
 The Oncology Nursing Society (2008) has prioritized symptom management for all 
aspects of nursing practice.  A symptom is defined in many ways, but there is a consensus in 
most sources that it is a persistent, subjective, physical or emotional phenomenon that 
accompanies a pathological condition.   
Brain-derived neurotrophic factor, also known as brain-dependent neurotropic factor 
(BDNF), is required for the differentiation and survival of specific neuronal subpopulations in 
both the central and the peripheral nervous system.  The Val66Met SNP gene variant for BDNF 
controls the expression and quantity of BDNF active within an individual.  In many studies, the 
method used for the analysis of the circulating biological indicators is the enzyme-linked 
immunosorbent (ELISA) assay (Leng et al., 2008).  For this study, genetic testing was completed 
to establish the presence or absence of the BDNF Val66Met SNP, but there was no testing for 
circulating BDNF.  The Conceptual Framework Diagram (see Figure 1) demonstrates the process 
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of investigating how the relationship between the BDNF Val66Met SNP and symptoms was 
conceptualized in this study. 
 
 
 
Figure 1. Conceptual framework diagram for the primary research question. 
 The study aims (primary and secondary) focus on several concepts: self-reported 
symptom occurrence and severity, daily activities performance, self-care, health-related quality 
of life, and the biological marker (presence/absence of the BDNF Val66Met SNP).  Figure 2 
illustrates the physiological relationships, such as how BDNF levels may impact symptoms.  
These are further described in the literature presented in Chapter 2.  The model was developed 
by Ken Kirschner, Research Associate at the University of Delaware neuroendocrine laboratory.  
Previous work was conducted in cooperation with this laboratory by this researcher as an 
amendment to the study by P. D. Williams (2009) entitled  Symptom Alleviation and Self-Care 
Methods During Cancer Treatment (KUMC-HSC #12048).  Biomarkers provided important 
information on the hypothalamic-pituitary-adrenal (HPA) axis and the sympatho-
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adrenomedullary (SAM) system, which were important in the development of the following 
model (Heinze, 2010b).    
 
Figure 2.  Proposed neuroimmunoendocrine model for the etiology of cancer-related symptoms. 
HPA = hypothalamic pituitary adrenal; CNS = central nervous system; BDNF = brain derived 
neurotrophic factor; NE = norepinephrine; GR = glucocorticoid receptor; CRH = corticotropin-
releasing hormone; PFC = prefrontal cortex; SNP = single nucleotide polymorphism. (From 
Dantzer, 2001; Duman & Monteggia, 2006; Raison & Miller, 2003) 
 
Although the model is complex, it was synthesized from the literature and provides a 
basis for how the effect of the BDNF Val66Met SNP, the variable under consideration in this 
study, relates to the physiological mechanisms that are influential in symptom etiology for the 
cancer patient.  Chronic inflammation related to cytokines and other substances may be 
implicated in the development of clusters of adverse symptoms; this study focused on the BDNF 
Val66Met SNP as the primary mode of detection for the more general inflammatory pathway. 
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The BDNF Val66Met SNP that causes a lower circulating level of BDNF could be an underlying 
cause of symptoms.  
Figure 3 shows the conceptual framework diagram for all three secondary research 
questions that explore the relationships of other variables to the cancer-related symptoms 
displayed in the pathophysiology model (Figure 2).   The concepts and empirical indicators 
(Dulock & Holzemer, 1991) that further explicate the model are shown in Table 1. 
 
 
 
 
 
 
 
 
Figure 3. Conceptual framework diagram for the secondary research questions. 
Table 1  
Concepts and Empirical Indicators for the Secondary Research Questions 
Concepts Daily activities Quality of Life Symptoms Sample 
characteristics 
Empirical indicators 
(operationalization) 
Daily Activities 
Rating Scale 
(DARS) 
5-item scale 
Health-Related 
Quality of Life-
Linear Analog Self 
Assessment 
(HRQOL-LASA) 
6-item scale 
Therapy Related 
Symptom Checklist 
(TRSC) 
25-item scale 
Five self-reported: 
age, ethnicity, 
education, 
treatment type, and 
time since treatment 
completion 
Level of 
measurement 
Ordinal Ordinal Ordinal Nominal/ordinal 
Analytic strategy Linear regression Linear regression Linear regression Linear regression 
 
 
Cancer-Related Symptoms 
Daily Activities 
Quality of Life 
Sample 
Characteristics 
Self-Care Methods 
Usefulness 
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 The measures have been used in previous studies by P. D. Williams and colleagues, and 
strong relationships with HRQOL-LASA (inverse) and DARS (positive) scores are related to 
increased TRSC scores.  The literature to fully illustrate these relationships is included in 
Chapters 2 and 3.  The treatment type and time since treatment completion are of particular 
interest since ongoing symptoms in breast cancer survivors is the focus of this study. 
Definition of Terms 
 Thirteen key terms have been selected and defined for the purpose of this study.  The 
terms are bolded and are listed alphabetically in the paragraphs that follow.  These are theoretical 
definitions; operational definitions appear in Chapter 3. 
BDNF Val66Met SNP is a common single nucleotide polymorphism in which the 
methionine (Met) allele replaces the valine (Val) allele in the pro-BDNF sequence.  This amino 
acid substitution is thought to result in diminished activity or trafficking of BDNF (Mandel, 
Ozdener, & Utermohlen, 2011). 
Biobehavioral symptoms are those that involve the “interrelationship among psycho-
social, behavioral and biological processes” (American Heritage Medical Dictionary, 2007).  In 
the model of the pathophysiology of cancer-related symptoms that appears earlier in this chapter, 
fatigue, depression, pain, anxiety, sleep disturbance, and cognitive function difficulty are given 
as examples of biobehavioral symptoms. 
Biomarkers are “biological parameters associated with the presence and severity of 
specific disease states” (U. S. Department of Health and Human Services, 2011).  The BDNF 
Val66Met SNP is a type of biomarker. 
A breast cancer survivor, as defined by the National Cancer Institute (2006), is an 
individual diagnosed with breast cancer from the day of diagnosis until the end of life.  For the 
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purpose of this study, breast cancer survivors will be women who have completed initial 
treatment for breast cancer previous to participation and would likely not be having acute 
symptoms related to treatment modalities or other co-morbid conditions.  More specific 
exclusion criteria will be covered in Chapter 3. 
Cancer-related symptoms are abnormal sensations or conditions that individuals 
experience as a result of cancer or its treatment. 
Cancer therapy regimen is the plan of treatment that may include surgery, radiation, 
and chemotherapy (American Cancer Society, 2007). 
 Chemotherapy is the use of drugs to destroy cancer cells.  A person on chemotherapy 
may take one drug or a combination of drugs.  Most often these drugs are given by intravenous 
infusion (IV), but some may be taken by mouth or given as a shot (American Cancer Society, 
2007).  Oral chemotherapy drugs commonly taken by breast cancer survivors include hormonal 
therapy such as Tamoxifen, Anastozole, or Letrozole.  
 Daily activities include those tasks that need to be completed in order to manage daily 
life.  This term was used in the rehabilitation literature as early as 1949.  It encompasses basic 
responsibilities, such as personal hygiene and feeding, up to more complex tasks, such as 
managing housework, finances, and community involvement (Frick, 2011). 
Genetic marker/indicator is a genetic sequence with a known location on a 
chromosome that may vary among individuals and can be used to identify characteristics or 
conditions of individuals for a purpose (DNA Junction, 2012).   
Genetic variant is a gene or DNA sequence that exists in different forms from one 
individual to another.  The variant may be as simple as a single base-pair change (single 
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nucleotide polymorphism, SNP), or as extreme as additional or missing copies of an entire 
chromosome (DNA Junction, 2012). 
Quality of life refers to the individual’s ability to enjoy normal life activities.  The 
evaluation of quality is a personal perception and is purely subjective. 
Self-care activities, for the purpose of this study, are defined as methods utilized to 
alleviate symptoms.  Some common self-care activities might include diet/nutrition/lifestyle 
changes, such as modifying food and eating habits, eating vegetables and fruits, using nutritional 
supplements, taking naps, and getting adequate rest and sleep.  Another type of self-care activity, 
described as mind/body control, includes activities such as prayer, meditation, or listening to 
music (P. D. Williams et al., 2006a; 2010a, 2010b). 
Symptom clusters have varying definitions.  Dodd, Miaskowski, and Paul (2001) define 
a symptom cluster as three or more interrelated, concurrent symptoms.  The concept of a 
symptom cluster is important to this study as it might suggest a common underlying cause.  With 
other researchers, the symptom clusters are shown also in the subscales of standardized, 
calibrated instruments (Williams et al., 1997). 
Summary 
In summary, this cross sectional study was conducted with a convenience sample of adult 
female breast cancer survivors who were at least six months out of treatment.  The study 
considered a biomarker, the BDNF Val66Met SNP, as a possible genetic indicator of occurrence 
and severity of symptoms.  Daily activities, self-care, and health-related quality of life were 
examined in relationship to symptom occurrence and severity, as well as in relationship to 
demographics and self-reported medical information (no medical records review was conducted 
to verify self-reported information).  The Oncology Nursing Society (2008) and other entities 
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emphasize the need for research in symptom management that could enable nurses to provide 
more personalized care. 
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Chapter II 
Literature Review 
This study was intended to determine if breast cancer survivors with the BDNF 
Val66Met SNP are more likely to suffer from a greater number of and/or more severe cancer-
related symptoms than survivors who lack this genetic variant (shown in Figure 2, in Chapter 1).  
Although circulating inflammatory cytokines and other substances are integral components of 
the chronic inflammatory model that may be implicated in the development of clusters of adverse 
symptoms, this study focused on the BDNF Val66Met SNP as the primary mode of detection for 
the more general inflammatory pathway.  The BDNF Val66Met SNP that causes a lower 
circulating level of BDNF could be an underlying cause of symptoms.  
This literature review is presented in six sections: (a) an overview of pathophysiological 
influences on symptoms, (b) personalized medicine, (c) the role of BDNF in breast cancer 
symptoms, (d) cancer-related symptoms/symptom clusters, (e) self-care, daily activities 
performance, and quality of life, and (f) a summary indicating the gap in the literature that may 
be met with this study.  Figures 1 and 2 (pp. 6 and 7) in Chapter 1 illustrate the relationships 
among the primary study variables.  
Pathophysiological Influences on Symptoms 
 Figure 2 (in Conceptual Framework, Chapter 1) illustrates the relationships between 
cancer symptoms and pathophysiological processes occurring in the human body.  
Proinflammatory cytokines, such as interleukin (IL)-1b, IL-6, and Tumor Necrosis Factor (TNF)-
α, have been shown to induce a condition known as “sickness behavior,” which has many 
overlapping features of the comorbidities experienced by cancer patients, such as depression, 
insomnia, cognitive impairment, and persistent fatigue (Dantzer, 2001).  One of the most 
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dramatic examples of the effects of cytokines on behavior is the neurophysiological sequelae of 
the cytokine-based immunotherapies, such as interferon and IL-2 (Capuron, Ravaud, & Dantzer, 
2001). 
 The ability of proinflammatory cytokines to alter behaviors indicates that the brain is 
capable of monitoring peripheral cytokine levels.  New research has provided evidence that 
cytokines are capable of not only signaling the brain via afferent nerves such as the vagal nerves 
(Quan, Whiteside, & Herkenham, 1998; Trakhtenberg & Goldberg, 2011) but are able to cross 
the blood-brain barrier at specific regions and enter the brain by volume diffusion (Banks, 2006).  
In addition, the brain contains immune cells, such as macrophages, dendritic cells, and microglia, 
that have cytokine receptors and can respond to inflammatory stimuli, producing their own 
proinflammatory cytokines and prostaglandins (Schlitz & Sawchenko, 2002).  Although the 
brain circuitry by which cytokines influence behavioral alterations is not fully understood, it is 
believed that these signals provide the brain with an image of the innate immune response 
occurring in the periphery.  In response to this inflammatory state, the Hypothalamic Pituitary 
Adrenal (HPA) axis releases cortisol, a potent anti-inflammatory hormone.  Under normal 
conditions, cortisol, in addition to many anti-inflammatory cytokines, will regulate the 
inflammatory response in an attempt to regain homeostasis.  However, if the inflammation 
becomes chronic, the HPA axis can become dysregulated (Raison & Miller, 2003).   
 The pathophysiological model underlying this study provides some evidence that the 
biobehavioral symptoms related to cancer may be caused by a cascade of events beginning with 
a chronic inflammation brought on by cancer, cancer treatment, and/or the stress of cancer 
diagnosis.  This inflammatory immune response results in the dysregulation of the HPA axis. 
This peripheral inflammation is mirrored in the brain, and the resulting neuroinflammation 
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interferes with neural plasticity and survival.  Damage to structures such as the hippocampus, 
prefrontal cortex, and the amygdala can result in the long-term biobehavioral changes that are 
exhibited by many cancer patients (Dantzer, 2001; Duman & Monteggia, 2006; Raison & Miller, 
2003). 
 How one responds to the physiological and psychological stress of breast cancer and 
treatment also may be a function of an individual’s coping strategy and resilience to extreme 
stress.  Coping strategy has been found to be a consistent predictor of a patient’s well-being 
during the cancer trajectory (Stanton et al., 2000).  Women who engage in problem solving and 
positive reappraisal, for instance, are less likely to be depressed than women who instead wish 
for the problem to go away (Carver et al., 1993).  How an individual responds to stress is 
influenced by her life experiences beginning in early childhood.  Fagundes, Lindgren, Shapiro, 
and Kiecolt-Glaser (2012) report that breast cancer survivors who experienced maltreatment as 
children experience more cancer-related symptoms and a poorer quality of life.  An individual's 
response to stress may also be associated with genetic factors, such as the BDNF Val66Met SNP 
mentioned above, thereby making her more vulnerable to persistent biobehavioral symptoms of 
cancer.   
Personalized Medicine 
Individualized medicine is a developing field in which decisions are tailored to individual 
patients in whatever way possible, including the use of information to select or optimize the 
patient’s preventive and therapeutic care (Price Waterhouse, 2009).  Variation in the human 
genome is common, with 1/1000 base pairs having a known variation, most of which are a single 
nucleotide polymorphism (SNP).  A SNP variation is not likely to afford a straightforward 
relationship to disease or symptoms, as many deviations in the patient and environment need to 
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be taken into consideration.  For example, certain genotypes have been linked to better survival 
in breast cancer, possibly due to better responses to chemotherapy (Ekhart, Rodenhuis, Smits, 
Beijnen, & Huitema, 2008).  Knowledge about the BRCA1 and BRCA2 gene mutation 
association of certain tumors has guided treatment of breast cancer for many years.  One study of 
breast cancer tumors identified 476 genetic variants in breast tumors that could impact prognosis 
(Chang, Hilsenbeck, & Fuqua, 2009).  It is possible that each of these genetic variants is an 
opportunity to craft a tailored treatment for the individual patient.  Cancer, in general, and breast 
cancer, in particular, seems to be the type of disease in which care could be personalized, 
including pharmacogenetics (Allen & Stewart, 2009). 
A genetic variant is produced when one or more nucleotides on a particular gene is 
changed.  The nucleotides provide instructions for the biochemical products, usually proteins, 
that are produced and activated by processes within the body.  The BDNF Val66Met SNP is a 
common single nucleotide polymorphism in the BDNF gene in which a methionine-coding (Met) 
nucleotide replaces a valine-coding (Val) nucleotide at codon 66.  This causes a valine amino 
acid to be replaced by a methionine at location 66 of the prodomain of the BDNF protein.  The 
presence of this SNP results in the impairment of intracellular trafficking and secretion of the 
BDNF protein.  Approximately two thirds of the population has a Val/Val homozygous 
genotype.  One third of the population has a Val/Met combination, and about one percent has a 
Met replacing the Val in both chromosomes, resulting in a Met/Met combination (Alexander et 
al., 2010). 
Increased insight into the mechanisms of action of biological determinants such as the 
BDNF Val66Met SNP may lead to more individualized treatments.  The presence of the BDNF 
Val66Met SNP was found to be a suitable indicator of poor outcomes in 105 survivors of 
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aneurysmal subarachnoid hemorrhage (Siironeen et al., 2007).  The BDNF Val66Met SNP has 
been shown to be a genetic modifier for severity in Rhett syndrome in a study of 125 mutant 
positive patients (Zeev et al., 2009). 
In 2008, a prospective study was conducted with a sample of newly diagnosed women 
with breast cancer (N = 1,539) for the purpose of creating a resource to examine behavioral and 
molecular factors and prognosis (Kwan et al., 2008).  The participants were enrolled within two 
months post-diagnosis during a 3-hour in-person baseline interview.  During the interview, 
anthropometric measurements were made, and questionnaires were administered concerning 
complementary and alternative medicine (CAM), physical activity, and psychosocial and quality 
of life measures.  A medical records review was also a part of the study, as the participants were 
part of a large Western insurance network.  Blood and saliva specimens were collected from 91% 
(1,398) of the 1,539 participants, creating a valuable biospecimen resource for genotyping, as 
well as testing for a number of circulating markers.  At 6 and 24 months from the date of the 
intake, interview follow-up questionnaires were mailed, and health status updates were done; 
additional follow-ups were completed at 1 year and at 36 months.  The final contact was made 
through a 48-month follow-up mailed questionnaire (Kwan et al., 2008).  The undertaking of 
such a large, complex study by an insurance carrier emphasizes the importance of and need to 
collect information to provide personal care for each individual undergoing treatment for breast 
cancer. 
The Role of Brain-Derived Neurotrophic Factor (BDNF) in Breast Cancer 
 Figure 2 (see Chapter 1, Conceptual Framework) illustrates the possible relationships 
between cancer symptoms and Brain-Derived Neurotrophic Factor (BDNF) in breast cancer.  
The dysregulation of the HPA axis, acting in conjunction or synergistically with a chronic state 
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of inflammation, has been linked to reduced neurogenesis and neural plasticity in the 
hippocampus and prefrontal cortex.  Neurotrophic factors, particularly BDNF and its 
tropomyosin-related kinase B receptor (TrkB), are critical regulators of neural plasticity, cell 
differentiation, cell survival, and neurotransmission.  BDNF is the most abundant neurotrophin 
in the brain.  The BDNF gene is located on chromosome 11p13 and controls the amount of 
BDNF produced.  One third of individuals have a gene variant for BDNF that causes its 
production to be greatly reduced.  Accumulating evidence suggests that low levels of BDNF play 
a role in the pathophysiology of a number of symptoms (Hashimoto, 2007), but the exact 
direction of the effect is not clear.  An animal study (Krishnan et al, 2007) found that mice with 
the polymorphism who were subjected to social defeat seemed to be less susceptible to ongoing 
change of behaviors related to the previous social defeat.  The polymorphism in this case seemed 
to provide a protective effect.  In contrast, a recently reported study with three experiments 
involving rats provided evidence for the role of BDNF in reducing resilience to the behavioral 
effects of stress.  In this study, both young and adult rats were subjected to maternal separation 
stress.  The stress resulted in reduction of hippocampal BDNF in the young rats but not in the 
adult rats, therefore resulting in chronic elevations of corticosterone in the young rats (Taliaz et 
al., 2011).   
In a different study, a sample of 57 genetically unrelated, healthy, paid subjects were 
tested for the Val66Met SNP.  There were 31 Val/Val, 19 Val/Met, and seven Met/Met 
genotypes carried by the subjects.  Two stimuli were defined for the study participants: A go task 
would be to push a button, and a no go task would be to refrain from pushing a button, 
depending on what prompt appeared on a computer screen.  A series of 300 simple go/no go 
tasks were presented on a PC-monitor, and subjects needed to respond by pushing a button with 
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their thumbs.  The results suggested a Met allele does affect response inhibition processes, with 
the Met/Met subjects having the best reaction times and making the fewest errors, resulting in 
these subjects being the most efficient at this simple task. The researchers boldly stated in their 
conclusion section that “our results, for the first time, reveal an evolutionary advantage justifying 
the conservation of the Met allele across generations” (Beste, Baune, Domschke, Faulkenstein, & 
Konrad, 2010, p.182).  
An MRI neuroimaging study of 209 multiple sclerosis patients, consisting of 140 
Val/Val, 62 Val/Met, and 7 Met/Met subjects, indicated that the Met allele was associated with 
lower damage (increased gray matter volume and lower lesion volume) on the images.  A 
subsample of 108 patients was tested cognitively; a trend toward better cognitive function in the 
subjects with the Val66Met SNP was demonstrated (Zivadinov et al., 2007).  Another study 
compared Vietnam veterans with traumatic brain injury (n = 121, 73 Val/Val, 45 Val/Met, 3 
Met/Met) to nonhead-injured Vietnam veteran controls (n = 47, 29 Val/Val, 16 Val/Met, 2 
Met/Met ), who served in Vietnam during the same years.  The groups were matched with 
respect to age, level of education, handedness, preinjury intelligence, and as many factors as 
possible from the extensive preinjury variables that were available in the military data set.  The 
investigators discovered, contrary to what they originally hypothesized, that the Val66Met SNP 
promoted functional recovery after traumatic brain injury (Krueger et al., 2011).  The Val66Met 
SNP has been demonstrated to have some positive benefits on cognitive processes with aging in 
a study of 131 healthy volunteers ranging in age from 65-88 (mean age 70.5, SD = 4.5), with the 
sample consisting of 79 subjects with Val/Val, 47 subjects with Val/Met, and 5 subjects with 
Met/Met.  The results of the study suggested that Val/Val carriers did not perform as well on 
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cognitive efficiency testing as did the Met-allele subjects (Gajewski, Hengstler, Golka, 
Falkenstein, & Beste, 2011).  
The role of BDNF in patients suffering from major depressive disorder (MDD) has 
frequently been studied.  Reduced BDNF levels are directly correlated to the degree of clinical 
impairment and hippocampal volume.  This model of neurotrophic depression is supported by 
evidence, indicating that many antidepressants function by increasing BDNF expression, 
increasing the TrkB signaling, and/or normalizing BDNF serum levels (Castren, Voikar, & 
Rantamaki, 2007).   
Recently, a SNP in the BDNF gene was described, in which a valine (Val) to methionine 
(Met) substitution at position 66 of the prodomain was identified (Egan et al., 2003).  The SNP is 
found only in humans and has been shown to be related to reduced hippocampal volume and 
poor hippocampus-mediated memory performance (Bath & Lee, 2006; Dempster et al., 2005; 
Egan et al., 2003; Szeszko et al., 2005).  This SNP has been utilized as a tool to determine the 
contributions of BDNF to the symptoms of various disorders, such as Post Traumatic Stress 
Disorder (PTSD; Frielingsdorf et al., 2010), diabetes (Gray et al., 2006), Parkinson’s disease 
(Ahlskog, 2011), anxiety (Hashimoto, 2007), schizophrenia (Lu & Martiowich, 2008), bipolar 
disorder (Grande, Fries, Kunz, & Kapczinski, 2010), and Major Depressive Disorder (MDD; 
Castren et al., 2007; Mata, Thompson, & Gotlib, 2010; Terracciano et al., 2011; You et al., 
2010).   
A meta-analysis of adult attention-deficit hyperactivity (ADHD) patients (1,445 from 
four European countries with 2,247 gender-matched controls) showed no association with 
BDNF.  The researchers listed several limitations: gender is likely a significant influence on the 
impact of the BDNF Val66Met SNP, and the ADHD population is predominantly male 
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(Sanchez-Mora et al., 2009).  The impact of BDNF levels has also been studied in additional care 
settings, specifically, in delirium patients in an intensive care unit (Grandi et al., 2011) and in the 
mental health of hemodialysis patients (Nishichi, Higashi, Washio, Todo, & Kumagai, 2011).  
The findings indicated that the presence of the BDNF SNP resulted in a negative effect on the 
outcomes measured with these patients. 
 Few studies have examined how healthy Val66Met individuals cope with acute or 
chronic stress.  Alexander et al. (2010) reported an attenuated HPA axis response in carriers of 
the Met allele compared to subjects with the Val/Val genotype.  In addition, Shalev et. al. (2009) 
reported a gender-dependent effect for the Met allele, with male subjects exhibiting a reduced 
cortisol response to a psychological stressor.  Further study to determine if there is a relationship 
to stress in females was recommended.  
A study conducted in Spain with 40 tissue samples of both mammary tumors and normal 
breast tissue implicated lowered BDNF as one of the important substances in differentiating the 
malignant tissues (Blasco-Gutiérrez, José-Crespo, Zozaya-Alvarez, Ramos-Sánchez, & García-
Atarés, 2007).  Aloe, Manni, Properzi, De Santis, and Fiore (2000) discovered lowered amounts 
of BDNF in the paws, bladders, and spinal cords of rats that had been given cisplatin, a 
chemotherapy agent that may cause neuropathy.  The discussion of the study includes a 
statement that the findings might be clinically useful as these are the anatomical target areas for 
the neuropathic symptoms. 
 Breast cancer and prostate cancer are often aligned in the literature due to their hormonal 
etiologies.  A study of tissue samples (16 prostate cancers and 20 benign prostatic hypertrophy 
growths) showed that the BDNF Val66Met SNP is expressed to a greater degree in malignant 
tumors (Bronzetti et al., 2008).  Fundamental questions remain concerning how these in vitro 
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effects relate to the in vivo consequences in humans.  According to Chen, Bath, McEwen, 
Hempstead, and Lee (2008), “It is possible that the identified genetic variant has a direct effect 
… but it is also plausible that the genetic variation mediates an effect through some other 
downstream functional change or through the regulation of some other gene” (p. 3).  The 
importance of understanding BDNF may help researchers discover why some individuals have 
severe decompensation for a certain situation and others do not, making these patients an 
important focus for clinical and preclinical studies (Pittinger, 2011).  
Cancer Symptoms 
 Although advances in detection and treatment of breast cancer have increased the 
survival rate for women over the past several years, many of these survivors continue to suffer 
from physiological and psychological late effects of treatment, which can seriously affect their 
quality of life, as well as their morbidity and mortality (Falagas et al., 2007; Mehnert & Koch, 
2008).  Demographics have demonstrated an important impact on symptoms in many studies.  
Recently, several large, cross-sectional studies provided support for this observation, including 
one study of 287 patients with mixed cancer diagnoses (Karabulu, Erci, Özer, & Özdemir, 
2010), and another of 703 breast cancer survivors (Ashing-Giwa & Lim, 2011).  In particular, a 
number of demographic characteristics have been shown to have an impact on Cancer-Related 
Fatigue (CRF).  For example, a 2010 study of Israeli women with breast cancer (Prigozin, 
Uziely, & Musgrave, 2010) indicated that education and age are inversely related to symptom 
severity and interference.  Current employment status and whether or not a woman has children 
living in her home were considered important factors in another study (Andrykowski, Schmidt, 
Salsman, Beachum, & Jacobsen, 2006).   
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Many studies have verified that the type of treatment impacts fatigue (Jacobsen, 
Andrykowski, & Thors, 2004).  Wu, Davis, and Natavio (2012) reported “a strong and 
potentially reciprocal relationship between cancer-related fatigue (CRF) and disrupted sleep-
wake patterns” (p. 181) that might indicate a shared physiological basis.  An important 
longitudinal study found that the type of therapy was one of the major significant contributors to 
CRF (Bower et al., 2000).  The same longitudinal study found that approximately 30% of breast 
cancer survivors reported persistent fatigue of unknown origin.  Linking fatigue to HPA axis 
dysregulation was accomplished in a later experimental study again led by Bower, Ganz, 
Dickerson, Aziz, and Fahey (2005).  Salivary cortisol measures were obtained from breast cancer 
survivors with persistent fatigue (n = 13) and a control group of nonfatigued survivors (n = 16), 
which correlated with blunted cortisol in the fatigued group (Bower et al., 2005).  A large (N = 
1,569) national cross-sectional study of patients receiving chemotherapy or radiation therapy for 
cancer found that 80% of patients reported fatigue, followed by 48% of patients reporting pain 
and 48% reporting nausea (Henry et al., 2008). 
Symptom Clusters 
Patients who have undergone cancer treatment often have multiple lingering symptoms, 
such as fatigue, insomnia, and depression, which commonly occur together and have come to be 
called symptom clusters (Agarwal, Hamilton, Moore, & Crandell, 2010; Barsevick, 2007; P. D. 
Williams et al., 1997a; P. D. Williams et al., 2001).  There are varying definitions for a symptom 
cluster.  Dodd et al. (2001) define a symptom cluster as three or more interrelated, concurrent 
symptoms, while others accept two symptoms as sufficient for a cluster (Kim et al., 2009).  With 
other researchers, the symptom clusters are defined by the subscales of standardized, calibrated 
instruments (P. D. Williams et al., 1997).   
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The methods used to determine the symptom clusters have varied.  For example, based on 
282 male and female patients with a wide variety of cancer diagnoses who were undergoing 
chemotherapy, radiation therapy, or both combined, the Therapy-Related Symptom Checklist 
(TRSC) symptom clusters were objectively derived or identified by P. D. Williams et al. (1997; 
2001) and A. R. Williams et al. (2000).  Principal components analysis resulted in a 25-item 
TRSC with 14 components or subscales, six of which were multiple items or symptom clusters.  
The symptom subscales or clusters were Fatigue, Eating Difficulties, Oropharynx, 
Nausea/Vomiting, Fever, and Respiratory-Related; the rest were single items (A. R. Williams et 
al., 2000).  Using discriminant analysis, the principal components differentiated between 
radiation and chemotherapy patients; thus, there is evidence of both discriminant and construct 
validity of the TRSC.  Skin changes, constipation, bleeding, decreased interest in sex, and 
oropharyngeal problems (sore throat, jaw pain) predominated in radiotherapy patients.  Hair loss, 
fever, bruising, nausea and vomiting, numbness of fingers and toes, and fatigue (feeling sluggish, 
difficulty sleeping) were predominant in chemotherapy patients.  Evidence of the reliability and 
construct validity of the tool were found (P. D. Williams et al., 1997; 2001).  Cronbach’s alpha 
of the TRSC multiple-item principal components all exceeded 0.70.  The final TRSC and 
Oncology Treatment Toxicity Assessment Tool (OTTAT) were correlated at 0.97.  The TRSC 
and functional status (Karnofsky) scores were significantly and inversely correlated (A. R. 
Williams et al., 2000; P. D. Williams et al., 1997).  It is noted here that the TRSC symptom 
subscale (cluster) labeled as Fatigue contains the symptoms of feeling sluggish, depression, 
difficulty concentrating, and difficulty sleeping.  Dodd et al. (2001) have reported a cluster 
containing similar individual symptoms.  
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In another study of 160 patients undergoing radiation therapy (78 females with breast 
cancer and 82 males with prostate cancer), Kim et al. (2009) identified symptom clusters using 
the 32-item Memorial Symptom Assessment Scale (MSAS) created by Portenoy et al. (1994).  
Three symptom clusters were identified: the mood-cognitive symptom cluster, the sickness 
behavior symptom cluster, and the treatment-related symptom cluster.  The symptoms in the 
mood-cognitive symptom cluster were difficulty concentrating, difficulty sleeping, feeling sad, 
sweats, worrying, itching, and feeling irritable.  The sickness behavior cluster included pain, lack 
of energy, and feeling drowsy.  The treatment-related symptom cluster included two symptoms: 
problems with urination and changes in skin.  Significant differences in all three symptom cluster 
severity scores were found between the females with breast cancer and the males with prostate 
cancer.  Patients with breast cancer had higher symptom cluster severity scores than the patients 
with prostate cancer for all three symptom clusters.   
A cross-sectional study of 400 newly diagnosed patients with inoperable lung cancer at 
two Swedish academic medical centers identified three slightly different symptom clusters 
(Henoch, Ploner, & Tishelman, 2009).  The study used a variety of instruments and statistical 
techniques.  The three clusters included a physical cluster consisting of pain, nausea, bowel 
issues, appetite loss, and fatigue; a mood cluster consisting of mood, outlook, concentration, and 
insomnia; and, finally, a respiratory cluster consisting of breathing and cough (Henoch et al., 
2009).  A cross-sectional pooled analysis of three studies of 154 patients with breast cancer 
resulted in a symptom cluster of fatigue, cognitive impairment, and mood issues based on a 
hierarchical cluster analysis of 13 symptoms using binary symptom variables within each study 
(Bender et al., 2008).  
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Patients who have multiple symptoms, such as those present in symptom clusters, 
perceive their symptoms to be more severe and debilitating (Gift, Jablonski, Stommel, & Given, 
2004).  Researchers suggest that by addressing symptom clusters instead of individual 
symptoms, negative patient outcomes could be minimized.  Later in the course of treatment, 
there seems to be a cumulative negative impact with the presence and combination of some 
symptoms (Given, 2008).   
Although there is no unifying explanation that accounts for all of these cancer-related 
symptoms, there is compelling evidence that chronic inflammation, involving a complex 
interaction between the central nervous system, the neuroendocrine system, and the immune 
system, may be the common etiological factor causing these biobehavioral symptoms.  Chronic 
inflammation is believed to play a major role in many pathophysiological and psychological 
disorders, including diabetes, coronary artery disease, chronic fatigue, metabolic syndrome, 
arthritis, and major depressive disorder (Antoni et al., 2006; Dantzer, O’Conner, Freund, 
Johnson, & Kelley, 2008; Miller, Ancoli-Israel, Bower, Capuron, & Irwin, 2008; Zunszain, 
Anacker, Cattaneo, Carvalho, & Pariante, 2010).  The presence of the BDNF Val66Met SNP, 
generally associated with lowered levels of circulating BDNF, may be an important biomarker 
for increased susceptibility to chronic inflammation, leading to biobehavioral cancer symptoms.  
The primary research question of this study sought to discover if there is a significant 
relationship between symptom occurrence and severity and the presence or absence of the BDNF 
Val66Met SNP.  
Self-Care, Daily Activities, and Quality of Life 
,  The use of a standardized patient-report symptom checklist (the Therapy-Related 
Symptom Checklist, TRSC), combined with corresponding measures of self-care and quality of 
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life (QOL), is the hallmark of many studies by P. D. Williams and colleagues.  The earliest 
study, with 91 adult oncology patients at three outpatient oncology clinics, was done in the mid-
1980s by practicing certified oncology nurses with over 40 years combined clinical oncology 
experiences between them (Youngblood, Williams, Eyles, Waring, & Runyon, 1994).  The 
purpose of the study was to compare the standard clinical interview responses, or “usual 
assessment” responses (for example, responses to the question, “How do you feel today?” that 
were documented in the charts and later copied and analyzed) of patients with those same 
patients’ self-reported responses and total scores on the newly developed Oncology Treatment 
Toxicity Assessment Tool (OTTAT), the precursor of the TRSC (described above in Cancer 
Symptoms).  Also, OTTAT scores were correlated with scores on the Quality of Life Index 
(QLI), a tool with good psychometric properties (Padilla, Presant, & Grant, 1983).  The key 
finding was that the number of symptoms recorded with the usual assessment (Mean = 1.5; SD = 
1.6; range = 0-9) was significantly lower than the mean number of symptoms reported using the 
checklist (OTTAT, Mean = 11.5; SD = 8; range = 0-37; t = 8.7; p = .001).  This showed 
significant under-reporting of symptoms with the usual assessment.  Concurrent validity also was 
shown with a significant correlation found between the symptom checklist score and QLI (r =     
-0.67, p = .0001).  Thus, higher symptom occurrence and severity (checklist total scores) was 
related to lower quality of life (total QLI scores).   
The literature also revealed that several studies were recently conducted using the TRSC 
in the United States, as well as in Asia, Europe, and Puerto Rico.  Two TRSC studies were 
published in 2006, including one with adults in a Midwestern state (P. D. Williams et al., 2006a), 
the results of which were further replicated in studies published in 2010 and 2011 and are 
described below.  The second study was conducted with children ( P. D. Williams, 
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Schmideskamp, Ridder, & Williams, 2006b), which formed the basis of an instrument 
development study on the newly calibrated instrument, the Therapy-Related Symptom Checklist-
Children (TRSC-C; P. D. Williams et al., 2012b).  The studies involving children are not further 
described here.   
Self-Care and Daily Activities 
The adult descriptive study (P. D. Williams et al., 2006a) was conducted with 37 adults 
receiving chemotherapy for leukemia, lymphoma, or breast cancer or for radiation for head and 
neck cancer.  Study participants reported their symptoms on the TRSC and also described the 
symptom alleviation methods they used to control their symptoms, a qualitative precursor of the 
Symptom Alleviation: Self-Care Methods (SA: SCM) quantitative tool used in the current study.  
The reported results showed that (a) 10 symptoms were reported as mild to moderate in severity, 
and 40% or more of the patients reported at least 17 symptoms on the TRSC; (b) care providers 
prioritized interventions based on the TRSC patient-reported symptom occurrence and severity 
scores; and (c) the self-care strategies, grouped according to complementary medicine categories 
as a framework, showed that the two categories most used were diet/nutrition/lifestyle change 
and mind/body control.  Responses also indicated the use of biological products, such as 
vitamins, and the use of herbal treatments and ethno-medicine, such as lime juice and garlic, 
green mint tea, and others, to alleviate symptoms.   
The same study was replicated in cancer centers in Hong Kong and in mainland China 
(Xi’an), using 222 adult oncology patients.  Similar methodology and instruments (with 
appropriate translation methods) were used, and good reliability, as well as validity, indicated by 
significant correlations between TRSC total scores and the Karnofsky functional status scale, 
were reported.  The findings were similar to the results of the study based in the Midwestern 
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United States.  Self-care strategies most often used fell in the same two categories 
(diet/nutrition/lifestyle change and mind/body control) and were reported as helpful by the 
patients.  Tai-chi was mentioned by some as part of mind/body control self-care measures 
utilized by the Chinese patients; biological treatments were also utilized (P. D. Williams et al., 
2010b).   
Another replication of the study was conducted with 100 oncology patients at the national 
medical center in Manila, the Philippines.  Findings similar to the studies conducted in China and 
the United States were reported.  The self-care methods most often used by patients in the 
Philippines fell into two categories.  The first type of self-care methods utilized were 
diet/nutrition/lifestyle changes, such as modifying food and eating habits, eating vegetables and 
fruits such as papaya, using nutritional supplements, taking naps, and getting adequate rest and 
sleep.  These self-care methods were all mentioned as useful to manage the symptoms in the 
Eating and Fatigue subscale symptoms.  The second type of self-care methods reported by 
patients were in the mind/body control category, such as prayer, praying the rosary, and listening 
to music; these self-care methods were used to relieve the symptoms in the Fatigue subscale, or 
cluster, as well as other symptoms (P. D. Williams et al., 2010a).  The key role of family support 
during treatment also was described by the patients, similar to findings on Filipino-Americans 
reported by Harle et al. (2007).  In TRSC replications with Puerto Rican patients and Mexican-
American patients undergoing treatment for cancer, two other studies have reported similar 
quantitative findings.  Moreover, qualitative findings have shown that patients focused on 
religious practices and utilized the support of family as part of self-care strategies (Gonzalez, 
Williams, Tirado, & Williams, 2011; Lantican, Williams, Bader, & Lerma, 2011), similar to 
practices employed by the patients in the Philippine study.   
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Another replication study was conducted in Thailand using the TRSC and similar 
methods, with a convenience sample of 202 patients receiving treatment for cancer at the 
National Cancer Institute, as well as at a cancer center of a provincial city in Thailand 
(Piamjariyakul et al., 2010).  The results closely mirrored those previously reported in the studies 
conducted in the Midwestern United States, mainland China, and the Philippines.  One of the 
unique self-care findings reported in Thailand was the use of the herbal treatment “purple 
flower” for hair loss.  The use of music and religious icons were also common, including the use 
of tapes related to Buddhist prayers.   
Recently, P. D. Williams et al. (2011b) reported the inter-correlations among the 
variables of symptom occurrence and severity (as measured by the TRSC), daily activities 
performance, self-care strategies, and health-related quality of life.  This study has been 
replicated in Puerto Rico (Gonzalez et al. 2010) and with Mexican-Americans (Lantican et al. 
2011).  The current study now adds an investigation of the potential linkage between the 
presence or absence of the BDNF Val66Met SNP (a genetic marker) and the occurrence and 
severity of symptoms experienced by breast cancer survivors after their cancer treatments have 
ended.  Thus, over several years, the work by P. D. Williams and a variety of U.S. and 
international colleagues has provided rich quantitative data through the use of calibrated 
instruments, as well as qualitative data to give insights into how self-care is related to cancer 
treatment-related symptoms.  Gathering information about common symptoms and monitoring 
the success of patient self-reported strategies can guide nurses in helping patients optimally 
during treatments for cancer (P. D. Williams et al., 2006a).   
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Quality of Life  
Tested for potential use in evidence-based nursing practice on a small sample of cancer 
patients, a study by P. D. Williams et al. (2011b) found that use of the TRSC for symptom 
management by advanced practice nurses resulted in a higher quality of life in the intervention 
group, as compared to the group receiving usual care.  Patients also reported that symptom 
assessment using the TRSC and ensuing symptom management had enhanced patient-nurse 
communication.  Moreover, in a sequential cohort design in a health services study on 113 
patients done at a Midwestern cancer center, findings showed that (compared to usual care), the 
use of the TRSC resulted in significantly higher patient-reported quality of life and functional 
status as measured on the Karnofsky scale, and significantly more symptoms were documented 
and managed (P. D. Williams et al., 2011b, 2012a).  
The symptoms associated with cancer and cancer treatments impact quality of life 
(QOL), but self-care can be a mediating factor.  In a study of lung cancer patients, John (2010) 
focused on personal strategies to promote quality of life.  The concept of self-care is represented 
in many ways in the literature, including the use of several synonymous terms.  A recent 
delineation of self-care and associated concepts was published in the Journal of Nursing 
Scholarship (Montazeri, 2008).  This important work was based on a review of 65 articles, book 
chapters, and books, representing the years 1994-2010.  The review included tables of 
commonalities, concept relationships, and a conceptual model depicting the five terms that are 
often used interchangeably in the literature: self-care, self-management, self-monitoring, 
symptom management, and self-efficacy.  The consequences of self-care, as represented in the 
literature, included improved quality of life and symptom management (Richard & Shea, 2011).  
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Quality of life (QOL) has also been the subject of at least 606 studies in breast cancer 
patients from 1974 to 2007 (Montazeri, 2008).  From the time of diagnosis through the entire 
continuum of life as a survivor, there are situations that can cause psychosocial distress and 
impact quality of life (Lacovara & Ray, 2007).  For instance, decision making about treatment 
can cause distress for patients, particularly for breast cancer patients.  Patient preference is the 
guiding principle for making treatment decisions in early stage breast cancer (National Guideline 
Clearinghouse, 2010).  Measuring satisfaction with the decisions that patients had made was the 
subject of a pre-post design study.  A nine-item tool was administered to a convenience sample 
of 30 early stage breast cancer patients of one surgeon at a large university medical center in the 
Southwest United States.  Although only 19 of the patients completed the 6-month follow-up 
phase of the study, there was an indication that nurses played a crucial role in advocating for the 
patients’ ability to make surgical treatment decisions with which they were satisfied (Lacovara, 
Arsouman, Kim, Degan, & Horner, 2011). 
In another study, nine women who were receiving chemotherapy for various types of 
cancer reported that the side effects, particularly nausea and vomiting, impacted daily life and 
decisions about future treatment (Bergkvist & Wengström, 2006).  The importance of measuring 
QOL from the patient perspective is emphasized in one early study of 130 cancer patients 
receiving either chemotherapy or radiation therapy.  The participants completed a 14-item visual 
analog quality of life measure.  The purpose of the study was evaluation of the instrument using 
a healthy (nonpatient) comparison group.  Interestingly, concurrent validity with physician rating 
of quality of life was very poor (Padilla et al., 1983).  A more recent study illustrated the 
practitioner-patient dichotomy in view of QOL.  Rossman (2004) stated that the onset of hair loss 
is the second most traumatic event after initial communication of the diagnosis of cancer, making 
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it an incredibly important moment in the cancer-related quality of life trajectory.  Health-care 
providers often minimize the importance of alopecia, as it is temporary and easy to remedy.  
Unfortunately, the literature indicates that this opinion fails to reflect the patient view.  Hair loss 
as a consequence of cancer treatment is a constant reminder to the patient of her disease.  
Freedman (1994), in a study about hair loss and breast cancer patients, wrote: 
Embodied in the symbolism of hair is a concept of the whole self, a completed 
person, who has the possibility of expressing individualism through the design of  
her hair.  The loss of hair is an extremely traumatic experience precisely because  
it is a symbolic precursor to the loss of self. (p. 336) 
An independent study of 20 patients conducted by Heinze (2010a) at an additional 
approved site for HSC#12048 (P. D. Williams et al., 2009) found that patients provided more 
care to alleviate hair loss than any other symptom.  For example, they wore a wig, hat, or scarf; 
cut their hair short; or shaved or massaged their heads.  There were individuals who wore wigs 
only on special occasions; conversely, one patient reported wearing it constantly, even in bed.  
The finding that all of the eight patients who reported hair loss as a symptom listed a 
corresponding self-care action emphasized the importance of this symptom to cancer patients.  
 Borsellino and Young (2011) sent a six-item survey electronically to 1,322 women 
cancer survivors as part of an e-newsletter for a group that helps women cope with the emotional 
upheaval of medical hair loss; the survey yielded 319 responses.  The data gathered led to the 
conclusion that preparation for cancer-related hair loss could be a pivotal point in the quality of 
life for patients.  Those who were well-prepared by nurses and proactively engaged in 
anticipatory coping for this symptom engendered a feeling of control that impacted their total 
symptom experience.  
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In another study, 206 responses to a mailed survey of multiple myeloma patients 
indicated that pain and mood disturbances had a significant impact on their quality of life 
(Poulos, Gertz, Pankratz, & Post-White, 2001).  In a secondary data analysis, 263 chemotherapy 
patients’ responses showed that insomnia, fatigue, depression, and anxiety were negatively 
correlated with quality of life (Redeker, Lev, & Ruggiero, 2000).  A six-month longitudinal 
study of 291 individuals diagnosed with multiple sclerosis indicated that individuals with the 
lowest scores on symptoms had the highest QOL. Those participants who had the highest scores 
in fatigue, pain, and depression had the worst QOL (Motl & McAuley, 2010).  A study 
conducted at a university hospital in Sao Paulo, Brazil, used four measures to explore the impact 
of cancer-related symptoms synergisms on QOL and performance status.  The participants were 
outpatients not receiving active treatment for their cancer.  They were divided into two groups: 
one group had multiple and severe symptoms and the other group had fewer symptoms with less 
severity.  Those patients in the multiple symptom group were six times as likely to report poor 
role functioning, five times more likely to have poor emotional quality of life, four times more 
likely to have poor overall QOL, and three times more likely to have poor cognitive and social 
QOL.  The only single symptom that had a negative impact on QOL was depression.  These 
results were independent of gender, age, level of education, and economic condition.  The 
researchers concluded that there is a synergistic effect among symptoms that result in reduced 
QOL (Ferreira et al., 2008). 
Predictors of quality of life in elderly hospice patients with cancer were the focus of a 
study of 533 adults (Garrison, Overcash, & McMillan, 2011).  Of the variables studied, number 
of symptoms, depression, and functional status accounted for 46% of the variance in quality of 
life.  
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Tofthagen (2010) reported on 14 cancer patients’ experiences with peripheral neuropathy. 
The semi-structured, private interviews indicated that neuropathic symptoms interfered with 
many aspects of daily life, resulting in frustration and depression due to the need to give up 
enjoyable activities that decreased their quality of life.  
The Montazeri (2008) review of the literature on health-related quality of life in breast 
cancer patients included a table listing 27 studies linking quality of life to common symptoms in 
breast cancer patients.  Seven studies focused on fatigue, six on lymphedema, five on hot flashes 
or menopausal symptoms, three on surgery-related symptoms, two on tamoxifen-related 
symptoms, and one each on pain and sleep difficulties.  All 27 studies illustrated symptom 
impact on quality of life. 
Symptoms research concerning fatigue has been commonly associated with quality of life 
and interference with self-care.  Fatigue is often described in the literature as one of the most 
common and distressing ongoing symptoms experienced by cancer survivors.  An estimated 80% 
to 100% of people with cancer experience fatigue (Gonzalez et al., 2011; Lantican et al. 2011; 
Prue, Rankin, Allen, Gracey, & Cramp, 2006; Servaes, Verhagen, & Bleijenberg, 2002; P. D. 
Williams et al. 1997; 2001; 2006a; 2010a, b).  Fatigue may be related directly to the cancer or its 
treatment and may continue for years after treatment is completed (Wang, 2008).  Despite its 
prevalence, there is still much to learn about fatigue in breast cancer.  
A literature review that culminated in a live focus group with the authors (Zee & Ancoli-
Israel, 2009) sought to address effective management of sleep disorders to reduce cancer-related 
fatigue yielded several specific recommendations for underlying mechanisms for cancer-related 
fatigue (similar to those raised in this study).  For example, areas of particular interest for further 
study and discussion included the following:  
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How is any apparent relationship between sleep and CRF driven by the various 
mechanisms they affect (e.g. inflammatory markers, circadian rhythm disturbances, 
depressed mood, HPA axis dysregulation)?. . .  What mechanisms underlie the effects of 
various cytokines in sleep-related pathologies, and how are these influenced by 
pharmacological agents? (Zee & Ancoli-Israel, 2009, p. 39) 
This study, as well as many other studies, raised the issue of exploration of biological 
mechanisms in conjunction with symptoms as a recommendation for future research.  
Summary 
 The pathophysiology of cancer-related symptoms has been reviewed.  Based on the 
available literature, the question of whether the BDNF Val66Met SNP is a possible genetic 
modifier of symptom occurrence and severity has not been examined in previous breast cancer 
studies.  This study fills in the gap by exploring a possible relationship between the presence or 
absence of the BDNF Val66Met SNP and symptom occurrence and severity in breast cancer 
patients.   
Targeting therapy toward the underlying symptom etiology is the crux of personalized 
medicine, an issue that has not been explored in nursing management of symptoms in breast 
cancer patients.  The discovery of a relationship between cancer-related symptoms and 
particularly symptom clusters to the BDNF Val66Met SNP might be an important first step to 
personalized nursing care.  The ability to relieve or decrease all symptoms in a cluster makes the 
research to discover common biological mechanisms an important endeavor (L. A. Williams, 
2007).  Investigating the relationship between the BDNF Val66Met SNP and the occurrence and 
severity of patient-reported symptoms, as well as the relationship between symptom-based 
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alleviation and self-care, has the potential to lead to a much-improved quality of life for cancer 
patients.   
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Chapter III 
Methodology 
Research Design 
 This study used a cross-sectional design with two phases: (a) Phase 1, an electronic 
survey collecting data on symptoms occurrence and severity, daily activities, and quality of life; 
and (b) Phase 2, the collection of physiological data and symptom alleviation self-care methods.  
Using inclusion criteria, an enriched sample was selected for Phase 2.  The subsets of Phase 1 
participants included in Phase 2 were the top and bottom scorers on the Therapy-Related 
Symptom Checklist (TRSC).  The top scorers (n = 25) had TRSC scores ranging from 23-54; the 
bottom scorers (n = 26) had scores ranging from 0-14.  This design maximized the variation 
between the groups on the dependent variable, the TRSC total score, as well as reduced the 
number of individuals for the most costly aspect of the study, the BDNF analysis.  
Primary Research Question 
Is there a significant relationship between symptom occurrence and severity in breast cancer 
survivors and the presence or absence of the BDNF Val66Met SNP?  
Secondary Research Questions 
1. What are the occurrence and severity of symptoms among breast cancer survivors as 
reported on the TRSC after the completion of their cancer therapy regimen?  
2. Are there significant relationships among symptom occurrence and severity, daily 
activities ratings, and health-related quality of life and selected demographic and other 
variables (age, ethnicity, education, treatment method, and time since treatment)?   
3. What self-care methods are used by survivors to alleviate symptoms, and what are the 
survivors’ perceptions of the usefulness of these self-care methods?  
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Setting of the Study 
The Mid-Atlantic states in which the data were collected have over one million residents, 
according to the 2010 census.  The residents of the state from which the majority of subjects 
were enrolled are mainly Caucasian (69%) and Protestant (51%).  Residents responding with “no 
religion” combined with those refusing to answer the census question regarding religious 
preference totaled over 20% of the responses, and 9% reported being Catholic.  In the state, 21% 
of the residents are black, 3% are Hispanic, 3% are Asian, and 3% are two or more races.  The 
largest employer in the state is the government, including a large number of positions in the 
military, followed by the fields of education, banking, chemical industry and pharmaceuticals, 
health care, manufacturing, and agriculture (Hartley, 2004). 
Sample  
 The convenience sample of volunteer participants was initially recruited from the data 
base of a statewide breast cancer coalition of a single Mid-Atlantic state.  When additional 
subjects were needed, recruitment was expanded to a number of hospital-based survivor groups 
and the local and state chapters of a national breast cancer organization in neighboring states.  
The study had two phases: (a) Phase 1, an electronic survey collecting data on symptom 
occurrence and severity, daily activities, quality of life, as well as subject characteristics, 
medication, treatment, and other health information (no medical records review was conducted to 
verify self-reported health and treatment information); and (b) Phase 2, the collection of 
physiological data and self-care information.  In Phase 1, breast cancer survivor respondents 
completed the online questionnaires.  Using inclusion criteria, an enriched sample was selected 
for Phase 2.  The subset of Phase 1 participants included in Phase 2 completed a measure of self-
care, as well as provided a salivary sample for the BDNF Val66Met SNP.   
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Inclusion and Exclusion Criteria 
Since a maximum number of participants were desirable in Phase 1, the only exclusions 
from the original data base were (a) all males, (b) females under 18 years of age, and (c) breast 
cancer patients at less than six months post treatment completion.  Protection of human subjects 
is an important primary concern in all research.  The study was approved by the University of 
Kansas Cancer Center Protocol Review and Monitoring Committee (PRMC) and KUMC Human 
Subjects Committee (HSC) before recruitment began; the approval form is included in Appendix 
A.  Breast cancer survivors were sent an electronic invitation to participate.  A copy of the 
invitation email is included in Appendix B.  
 The main inclusion criterion was an adult female breast cancer survivor who completed 
therapy six months or more prior to the survey.  The url link to the electronic survey (see 
Appendix C) was sent via email to all potential participants listed in the coalition data base, 
inviting them to involve themselves in the research.  The Phase 1 survey instrument was 
composed of the TRSC, Daily Activities Rating Scale (DARS), Health Related Quality of Life – 
Linear Analogue Self Assessment (HRQOL-LASA), and the Demographic and Health Form.  As 
shown in the Phase 1 packet, the Demographic and Health Form included questions related to 
any “current illnesses” and to “medicines currently taken” in order to be able to evaluate the 
possible impact of current illness or medication on the study variables.  Tables 1 and 2 in the 
section Data Collection Procedures outline the specific steps followed in the study.   
Instruments 
The study variables were self-reported symptom occurrence and severity; self-care; daily 
activities performance; health-related quality of life; and the presence or absence of the genetic 
variant, the BDNF Val66Met SNP.  Measurements are described below, along with selected 
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demographic and other variables (age, ethnicity, education, treatment type, and time since 
treatment completion). 
Therapy-Related Symptom Checklist.  The first instrument included as items 2-27 of 
the electronic survey was the Therapy-Related Symptom Checklist (TRSC).  See Appendix D for 
the paper and pencil version of the instrument for comparison.  Patient-reported occurrence and 
severity of symptoms were operationalized by the total score on the TRSC.  The Cronbach’s 
alpha of the total scale score for this study was 0.91.  The study participants indicated the 
occurrence of symptoms experienced by checking whether the symptom was present and then 
rating the severity of each symptom on a 5-point scale, from 0 (none) to 4 (very severe).  Space 
was provided to write in and rate other symptoms that were not listed.  The 25 items were 
summed (range 0 – 100), where higher scores on the TRSC indicated greater frequency 
(occurrence) and severity of symptoms reported.  The psychometric properties of the TRSC are 
reported in Chapter 2. 
Symptom clusters. The TRSC has fourteen subscales developed through the use of 
principal components analysis (P. D. Williams et al., 1997, 2000) and subsequently used in 
numerous studies by P. D. Williams and colleagues.  The conceptual framework and literature 
search for this study supported the fact that a biomarker, such as the BDNF Val66Met SNP, may 
display its impact through the grouping or clustering of symptoms.  Eight of the subscales are 
single item scales (Pain, Numbness in Fingers and/or Toes, Bleeding, Hair Loss, Skin Changes, 
Constipation, Soreness in Vein, and Decreased Interest in Sexual Activity).  The two longest 
subscales contain four items each.  The Fatigue subscale consists of the items feeling sluggish, 
depression, difficulty concentrating, and difficulty sleeping.  This Fatigue subscale contained the 
four items that are consistent with biobehavioral symptoms.  These four items were not scored to 
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create a subscale but used individually in a subanalysis for the primary research question.  The 
other four-item subscale, Eating, includes the TRSC items of taste changes, loss of appetite, 
weight loss, and difficulty swallowing.  There is one three-item subscale designated as 
Oropharyngeal that includes sore mouth, sore throat, and jaw pain.  The remaining three 
subscales included two items each: Nausea (nausea and vomiting), Fever (fever and bruising), 
and Respiratory (cough and shortness of breath).  However, all of the items were considered 
individually and not scored as subscales for this study. 
 Daily Activities Rating Scale. The second instrument (items 28-32 on the electronic 
survey) was the Daily Activities Rating Scale (DARS).  The Cronbach’s alpha for this survey 
was 0.70.  See Appendix E for the paper and pencil version for comparison.  The daily activities 
rating total score queried about level of ease or difficulty in performing Activities of Daily 
Living (ADL), with higher scores reflecting more problems performing ADLs.  The five items on 
this scale are related to respondents’ levels of ease or difficulty in performing ADLs, answered 
on a scale of 1 (not at all) to 4 (very much).  For example, Item 29 asks: “Do you have any 
trouble taking a long walk?”  The scale ranges from one to twenty; thus, higher scores reflect 
more problems performing ADLs.  Basch et al. (2007) reported concurrent validity of this scale 
with established, longer scales.  Construct and discriminant validity also showed strong, positive 
correlations between scores on this instrument and the total scores on the TRSC (Gonzalez et al., 
2011; P. D. Williams et al., 2011b). 
Health-Related Quality of Life - Linear Analogue Self Assessment. The third 
instrument, items 33-38 of the electronic survey, was the Health-Related Quality of Life - Linear 
Analogue Self Assessment (HRQOL-LASA; see Appendix F for the paper and pencil version). 
The HRQOL-LASA is used to measure health-related quality of life.  The HRQOL-LASA has 
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six items that use a 10-point scale, from 0 (as bad as it can be) to 10 (as good as it can be).  
Scale scores range from 0 to 60, with a high score on the HRQOL-LASA indicating a high 
quality of life.  The Cronbach’s alpha for this usage was 0.93.  The items have been validated as 
general measures of global QOL dimensional constructs in numerous settings (Bretscher et al., 
1999; Grunberg, Groshen, Steingass, Zaretsky, & Meyerowicz , 1996; Gudex, Dolan, Kind, & 
Williams, 1996; Hyland & Sodergren, 1996; Sloan et al., 2002; Sriwatanakul et al., 1983; 
Wewers & Lowe, 1990).  The series of six LASA items were constructed and validated at Mayo 
Clinic for use in cancer patients (Bretscher et al., 1999).  A community-based, translational 
research study conducted by P. D. Williams et al. (2011a, 2012) on self-reported symptoms on 
the TRSC as related to symptom management in the context of a oncology care delivery system 
was completed online by 138 oncology patients during repeated treatment clinic visits (for 
chemotherapy, radiation therapy, or a combination of both) and was found significant.  The 
researchers discovered strong inverse correlations between total scores on the TRSC and 
HRQOL-LASA.  Moreover, the HRQOL-LASA overall physical well-being item was most 
strongly correlated with the TRSC total score.  Construct and discriminant validity also have 
shown strong, inverse correlations between scores on this instrument and the total scores on the 
TRSC (Gonzalez et al., 2011; P. D. Williams et al., 2011b). 
Subject Characteristics and Health Form. Subject characteristics and health 
information were obtained via electronic survey items 39-47 (see Appendix B).  Subject 
characteristics and other data collected for Phase 1 included the respondent’s age and ethnicity.  
Other self-reported medical information (medications, co-morbid conditions, and treatment 
modality) were collected, as they were important in the context of the symptom literature.  The 
last part of the electronic survey included a section (a) inviting participants to join study Phase 2, 
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briefly described, and (b) requesting that they provide information to enable the researcher to 
contact those respondents who met the inclusion criteria for Phase 2 participation.  A subject 
characteristics form in the electronic survey included items that have been modified from those 
used in previous studies by P. D. Williams and colleagues (Heinze, 2010a, b; Piamjariyakul et 
al., 2006; P. D. Williams et al., 2006a, b; 2009; 2010a, b; 2011a, b, c).  Some adaptations of the 
subject characteristics selected for this study were made based on the literature and the options 
for the selections available in the electronic format.  Adaptations also were made based on the 
most common responses given on the 2010 census by residents of the state from which the 
majority of respondents were drawn.  Previous use of the subject characteristics in pilot studies 
was helpful in refining the variables selected. 
Subject characteristics were chosen as variables for the study because they have been 
shown to impact symptoms in breast cancer patients in previous studies.  A study of Israeli 
women with breast cancer (Prigozin et al., 2010) indicated that education and age are inversely 
related to symptom occurrence and severity.  Current employment status and whether or not a 
woman has children living in her home (Andrykowski et al., 2006) were considered important 
for the study, although no significant differences were found among the variables in this sample.  
Type of therapy and time since completion of therapy were found to be significant in a major 
longitudinal study (Bower et al., 2000).  Marginal differences in the symptom of fatigue were 
demonstrated for lower income levels and marital status in the same study.  In a cross-sectional 
study of 703 multiethnic breast cancer survivors, the main conclusion was that HRQOL is 
closely linked to demographic contexts and influences emotional well-being.  The implication 
for nursing was to use the subject characteristics to inform and enhance the assessment of 
emotional outcomes for clinical and scientific purposes (Ashing-Giwa & Lim, 2011).  
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 Symptom Alleviation: Self-Care Methods. The Phase 2 instrument, Symptom 
Alleviation: Self-Care Methods (SA: SCM; see Appendix G), was used by respondents to report 
self-care strategies performed to alleviate any symptoms experienced and marked on the TRSC. 
Frequency of use and effectiveness of the performance of self-care methods are operationalized 
by the SA: SCM.  The instrument is directly based on the symptoms checklist of the TRSC.  For 
each symptom reported, the patient was asked what methods were used to attempt to alleviate the 
symptom, and to rate how often each self-care method was done using the scale 1 (seldom done) 
to 4 (very often done). Scores ranged from 0 to 100.  Whether or not the method helped relieve 
the symptom was also asked (indicated by a check in a “yes” or “no” answer column).  Thus, the 
higher the score on the SA: SCM, the more often self-care was performed.  Cronbach’s alphas 
above 0.70 have been reported (Gonzalez et al., 2011; P. D. Williams et al. 2011b).  In addition, 
the construct validity of the SA: SCM was shown in a finding that higher depression scores were 
related to patient reports of self-care for nausea being "not helpful," as compared to patients with 
significantly lower depression scores, who reported that their self-care methods "helped."  
Similar results were found with the symptom of hair loss.  The study included a large number of 
Mexican-Americans (Lantican et al., 2011).  Moreover, on the TRSC Chinese version of the SA: 
SCM tool, a total of over 500 "helpful" self-care methods (SCMs) was reported as well as a few 
SCMs that were "not helpful."  The highest number of helpful SCMs mentioned was for the most 
frequently reported symptom of feeling sluggish (P. D. Williams et al., 2010a). 
BDNF Val66Met SNP.  Single nucleotide polymorphism (SNP) is a common genetic 
variant in which a single nucleotide is replaced with a different one (in this case methionine 
replaces valine).  Most SNPs have no effect on health or development while others may predict 
or influence an individual’s response to a medication, an environmental toxin, or his or her risk 
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of developing a particular disease.  A common SNP found in the BDNF gene (rs6265) results in 
an amino acid substitution of methionine (Met) for a valine (Val) at codon 66 and is designated 
as Val66Met.  Egan et al. (2003) reported that Met substitution leads to inefficient trafficking of 
BDNF to secretory granules leading to reduced BDNF in neuronal survival, differentiation, and 
synaptic plasticity.  The Val66Met SNP has been assessed for its potential contributions to 
symptoms of psychiatric illness and neurodegenerative diseases.  The presence of the BDNF 
Val66Met SNP in saliva was measured by genotyping in all Phase 2 subjects.  
Protection of Human Subjects 
Full information concerning the study was disclosed at the time that consent was given by 
participants.  The consent form (see Appendix H) included background, purpose, procedures, 
risks, benefits, alternatives, cost/payment, right to withdraw, and confidentiality.  The researcher 
was present to answer all questions before the subject signed the consent.  The copy of the 
consent that each of the participants received included the researcher’s contact information in the 
event that concerns, complaints, or additional questions should arise.  To protect confidentiality, 
each participant was assigned a code number that was used for identification of all data.  Since 
this study involved genetic testing, there was a special section of the form that explained the 
special requirements outlined by the KUMC Human Subjects Committee. 
Data Collection Procedures 
The data collection process was comprised of two phases (see Figure 3).  The study 
design involved collecting quantitative data first (Phase 1) to provide the basis for a purposive 
subsample (Phase 2).  This design maximized the variation between the groups on the variable 
symptom occurrence and severity, as measured by the TRSC total score, as well as reduced the 
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number of individuals for the most costly aspect of the study, the BDNF analysis.   Figure 4 
illustrates the data collection process. 
 
Figure 4. Study data collection procedures. 
Phase 1 
In Phase 1, the invitation to participate in this study (see Appendix B) was sent via email 
to the approximately 800 female breast cancer survivors who are included in the primary state’s 
coalition data base, along with the url that gave them access to the electronic survey (see 
Appendix C).  In order to prevent potential respondents from inadvertently deleting the email 
containing access to the survey, an announcement first appeared in the coalition's newsletter, 
notifying subscribers that an important survey would be coming by email.  Another method used 
to optimize participation was a recruitment announcement on the coalition Web site and 
Facebook page.  When additional recruitment became necessary, the coalition project director 
provided information for the researcher to contact leaders of other breast cancer groups in the 
area. 
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The electronic survey was formatted in Zoomerang™, a survey software package 
available through the hospital at which the researcher is employed.  The survey was developed in 
cooperation with the information technology director and the Webmaster at the hospital.  The 
coalition staff and dissertation advisor reviewed initial drafts, and corrections were made 
according to reviewers’ recommendations.  A pilot of 10 participants was then conducted. 
Additions were made to clarify the symptom time frame that was to be addressed by adding the 
word “current” to the introductory section.  Pages were adjusted to include only five or six items 
per page so that the mandatory item prompt would appear on each screen without the need for 
the participant to do extensive scrolling.  The questionnaire was designed with color, customized 
bolding, and spacing to improve the appearance, as a “fancy” questionnaire is more likely to be 
completed and has been shown to increase response rate by 5%; this type of motivation is 
important for increased response to Internet research (Im & Chee, 2003), and the cooperation 
with the coalition was assumed to be a good motivator.  There are seasonal response rate 
fluctuations to Internet research (Im & Wonshik, 2004), and the winter has been found to be a 
much better season to launch than summer, as the potential participants would be more likely to 
be indoors and attending to their computers during the more inclement weather.   
Collaborating with the breast cancer coalition for this study was integral to the feasibility 
and success of this project.  The researcher has worked in partnership with the coalition on 
various scientific projects for nearly four years, with excellent cooperation.  A data base was 
established to catalogue breast cancer survivors who have connected in a significant way with 
the coalition in terms of volunteering or having multiple, continuing contacts.  Part of the 
mission of the organization is to promote research to benefit breast cancer survivors.  The 
database has been used for previous studies.  The return rates traditionally have been very high 
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and are better for email than for traditional postal mailings, as noted by the special projects 
manager for the coalition.  The project director reported that 100% of subscribers on the email 
list have access to a computer at home or another accessible venue that they use routinely. 
 The recruitment email was sent from the coalition email address in order to avoid the 
possibility of the email being screened out as spam.  This list of subjects was used and updated 
often so that the number of undeliverable emails should have been small.  Once the electronic 
survey was launched on February 10, 2012, the returns were monitored.  A number of questions 
were recurring in emails sent to the researcher, so the first reminder that was sent included 
answers to those questions.  Unfortunately, one of the questions that was emailed to the 
researcher led to a discovery later that same day that there was a problem with the skip logic on 
the survey, and the first five questions were being omitted.  Attempts to resolve the situation 
were not successful, and the original survey was closed.  A supplemental survey including the 
missing five questions was emailed to those individuals who provided contact information for 
participation in Phase 2, and a new survey was launched.  The timing of the reminder was based 
on knowledge that responses normally will come within eight days (Sheehan & McMillen, 
1999).  Two or more reminders were sent, but the number of additional returns was not 
sufficient.  Additional participants were recruited until a total of 214 responses were received.  
The completed TRSCs were scored as they were received.  The returns were reviewed to see 
who had given consent to participate in Phase 2.  Table 2 provides an overview of the Phase 1 
data collection procedures. 
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Table 2  
 
Study Participant Data Collection Procedures, Phase 1 
  
Research activity Follow-up 
Email invitation to participate sent to 
approximately 800 survivors on coalition 
distribution list.  
Email reminders sent to those on the coalition 
list. 
 
Zoomerang™ was used to administer the 
survey through a url in an email and on the 
coalition Web site.  Eligibility criteria were 
listed in item 1, and individuals were screened 
from completing the survey if the eligibility 
criteria were not met.  The demographic form 
also included exclusion criteria information to 
provide a double check that only results from 
eligible participants were included.  
Email reminders were sent.  
Scored TRSC Those who completed the TRSC and provided 
contact information received follow-up 
contact. 
Phone calls were made to those giving initial 
consent beginning with highest and lowest 
scores until two groups were created (Group 1 
– 26 top scorers, and Group 2 – 25 bottom 
scorers) who satisfied the inclusion criteria. 
Locations for the collection of salivary 
specimens and completion SA: SCM were 
determined.  Inquiry was made about whether 
dry mouth would be an issue, and complete 
instructions about the amount and activities to 
avoid before salivary sample collection were 
reviewed, including good hydration. Each 
participant was contacted to confirm 
commitment to the date, time, and location. 
 
Phase 2  
Phase 2 began with selection of a purposive, or enriched, subsample of the original 
respondents.  The enriched subsample contained only those respondents willing to participate in 
Phase 2 who had high (≥ 23) and low scores (≤ 14).  To prepare for Phase 2, the locations for 
sample specimen collections were established based on the participants’ addresses and were 
coordinated with the assistance of the coalition special project manager.  Once the willing 
respondents from Phase 1 were screened, 51 individuals were selected for two groups based on 
their TRSC scores.  The first group consisted of the 26 individuals who had the highest total 
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TRSC scores (ranging from 23 to 54), indicating a high occurrence and severity of symptoms, 
and the second group of 25 was composed of the participants who had the lowest total scores on 
the TRSC (0 to 14), indicating minimal occurrence and/or severity of symptoms.  This procedure 
was followed in order to maximize the variability.  Dates for sample collection were scheduled, 
and each participant was contacted to confirm her commitment to the date, time, and location.  
Packets were prepared for each individual, including the SA: SCM and saliva sampling packets.    
All arrangements were made by the researcher to procure and prepare the site(s) before 
participants arrived.  Participants received individual reminders the day before the in-person data 
collection.  If any of the individuals were unable to keep the appointment, an effort was made to 
schedule an alternate appointment.  Table 3 describes the step-by-step method implemented in 
Phase 2 of the study for saliva sample collection.  Presence of the Val66Met SNP was 
determined by genotyping a single saliva sample collected from consenting subjects.  A 
transcript of the instruction video was available upon request.  The OG-500 data collection 
system was selected for use as this collection device has the proper design and components to 
promote ease of collection and protection of the integrity of the specimen.  The tube was a 
standard size, facilitating use in most laboratory equipment.  Most of the studies that require the 
collection of saliva samples have used the OG-500 because the instructions were clearly written 
and the device was easy to use.  If there was any difficulty obtaining the saliva sample, the 
subject was permitted to take a break or reschedule at another time.  
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Table 3  
 
Consent, Saliva Sample, and Instrument Collection Procedures, Phase 2 
 
Research activity 
Participants were welcomed and completed informed consent (see Appendix H). 
The SA: SCM was completed with the researcher. 
Researcher screened participants to ensure that they  
 did not have a cold or sinus infection, 
 had not consumed alcohol for 24 hours, 
 had not brushed their teeth, or had anything to eat or drink for two hours, 
 had not chewed gum or smoked for 30 minutes before collecting sample 
(Mandel, Ozdener, & Utermohlen, 2009, 2011). 
On arrival at the study site, the researcher gave the participants (a) the written instructions for 
saliva collection (see Appendix I), as well as answered any questions. 
 
Collection of salivary sample was directly observed and assisted by one researcher. The steps 
were for the participant were as follows: 
 
 Relax and rub cheeks for 30 seconds. 
 Allow the saliva to pool in their mouth, and imagine they are eating their favorite food. 
 Take all the time needed to deposit 2 ml of saliva (excluding foam) indicated by a fill 
line marking.  The time needed was generally no more than 2-5 minutes.  Several 
collections did take over 30 minutes, but the sample integrity was not compromised as 
the company certified that the sample remains stable for hours if collection is protracted.  
 The collection device was sealed as indicated by a loud click, releasing the buffer and 
raising the level of fluid in the tube. 
 While holding the tube upright, the funnel top was unscrewed and replaced with the cap 
provided.  
 Once the cap was in place, the tube was shaken for 5 seconds. 
 The sample was placed immediately in the shipping container marked with only the 
study identifier (no personal identifiers) and biohazard labeling and was transported or 
shipped according to instructions (Shipping Recommendations, 2009). 
Researcher administrated collection of instrument data and the departure routine, including a 
verbal thank you, and reviewed study material before departure. 
 
 BDNF Val66Met SNP data collection.  Presence of the BDNF Val66Met SNP was 
determined by a genetic test.  Consenting subjects were asked by the researcher to collect 2 ml of 
saliva using the passive drool method for saliva collection.  Passive drool method means that the 
patient simply spits into the specialized, sealable container up to the fill marker without any 
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swabs employed to stimulate or absorb the saliva.  Since saliva is naturally foamy, careful 
attention was given to assure that the liquid level was raised to the 2 ml marker or above, 
excluding foam or bubbles.  If the subject had difficulty producing the 2 ml of saliva 
recommended, the presampling method to stimulate salivation, massaging the jaws, could be 
repeated multiple times.  The laboratory where the samples were analyzed routinely reports a 
less than 1% problem with specimens, even though the majority of specimens are self-collected.  
This study included the safeguard of supervision.  A copy of the manufacturer's instructions for 
the patient is included in Appendix I.  The DNA Self-Collection Kit from DNA Genotek in 
Kanata, Canada, contained a DNA stabilizing buffer.  This buffer ensured stability of the sample 
for transport to the testing site without any specialized procedures.  The samples were 
transported to the Institute of Genomic Medicine (IGM) at the University of Medicine and 
Dentistry of New Jersey (UMDNJ).  The IGM is an academic contract research organization that 
provides evaluation of biomarkers.  The center for Medicare and Medicaid Services (CMS) 
developed Clinical Laboratory Improvement Amendments (CLIA) beginning in 1988, which 
provides the basis for CLIA certification.  The laboratory used was CLIA certified and College 
of American Pathologists (CAP) accredited.  The CAP's accreditation program is an 
internationally recognized program.  CAP assessors visit the UMDNJ laboratory every two years 
to perform an on-site assessment and evaluation according to CAP standards.  For DNA testing 
laboratories, such as the IGM lab at UMDNJ, CAP evaluates the techniques that the technicians 
use and ensures that they are complying with or exceeding national regulations (DNA Junction, 
2012).  UMDNJ affiliates with hospitals and academic institutions throughout the region and 
maintains an ongoing association with the neuroendocrine lab at the University of Delaware.   
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All subject samples were labeled with a code number to protect the identity of 
participants.  Samples received at the IGM laboratory were prepared for analysis using a strict 
protocol of incubation and ethanol rinses.  Samples were quantified for DNA content and then 
diluted to appropriate concentration for analysis.  UMDNJ laboratory personnel had specific 
probes and primers already available to amplify the region surrounding the Val66Met SNP.  The 
genotyping was completed using a Taqman probe assay for the presence or absence of the 
Val66Met polymorphism.  All testing was run in triplicate, and any variations in results for one 
subject’s sample prompted a quality check with samples run at varying dilutions for that subject.  
Three of the subjects’ samples needed to be repeated for the current study.  All cost associated 
with testing and materials were underwritten by the University of Delaware.  After the analysis, 
all saliva samples were destroyed. 
Plan for Data Analysis 
The methods of data analysis were selected due to their robustness in view of the sample 
size,  possible deviations from normal distribution, and variance issues.  Data analysis was 
limited to simple techniques that could be completed using Statistical Package for the Social 
Sciences (SPSS) version 20.  A theoretical approach was taken to assure that variables were 
conceptually intact when it was necessary to collapse categories or dichotomize for analysis. 
The primary research question for this study was as follows: Is there a significant 
relationship between symptom occurrence and severity in breast cancer survivors and the 
presence or absence of the BDNF Val66Met SNP?  This question was first analyzed using a 
Fisher’s exact test followed by logistic regression analysis.   
The first secondary research question was as follows: What are the occurrence and 
severity of symptoms among breast cancer survivors as reported on the TRSC after the 
 
 
55 
 
completion of their cancer therapy regimen?  Frequencies and descriptive statistics were used to 
address this question.  The standard descriptive statistics profile was used (including mean, 
median, and standard deviation; standard error of the mean; and minimum and maximum; Leech, 
Barrett, & Morgan, 2008).  
 The second secondary research question was as follows: Are there significant 
relationships among symptom occurrence and severity, daily activities ratings, and health-related 
quality of life and selected demographic and other variables (age, ethnicity, education, treatment 
method, and time since treatment)?   This question was addressed using Fisher’s exact test and 
linear regression. 
 The third secondary research question was as follows: What self-care methods are used 
by survivors to alleviate symptoms, and what are the survivors’ perceptions of the usefulness of 
these self-care methods?  This question was addressed by descriptive statistics and content 
analysis according to standard guidelines for organizing according to themes and concepts.  
Overview of Robustness of Data for Analysis 
Several possible selection biases were explored to examine the robustness of the data.  As 
previously discussed, missing data in Phase 1 was an issue.  Fortunately, there were no 
statistically significant TRSC score differences between the subjects with at least one item 
missing on the TRSC and the 135 subjects with no missing data (Levene’s test for equality of 
variances p = 0.010, t-test for equality of means p = 0.002).  There were no missing data for 
Phase 2 subjects.  Standard checking procedures for data entry were used to avoid missing data 
in processing.  Polit and Beck (2008) provided a framework for designing a quantitative analysis 
strategy from data collection through interpretation.   
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Another possible bias was whether or not the subject was interested in participating in 
Phase 2 of the study.  It is possible that there could be something unique about those subjects. 
However, there were no differences in age or ethnicity between the Phase 1-only subjects and 
those who were willing to continue to Phase 2, if selected.  One finding was that a larger 
percentage (56%) of the initial deployment respondents (n = 82) agreed to participate in Phase 2, 
while only 37% of the subsequent deployment respondents agreed to participate in Phase 2.  The 
simple explanation seems to be that the initial group was engaged and ready to participate fully, 
showing enthusiasm by replying within a week of the deployment.  In contrast, the remainder of 
the respondents came through some concerted recruitment efforts over a period of more than two 
months and may have been less enthusiastic about participation.  The methods of analysis were 
selected due to their robustness in view of possible deviations from normal distribution and 
variance.   
Missing data were a concern for this study that needed to be carefully considered when 
approaching analysis.  Technical problems with the initial survey deployment resulted in the first 
82 of the 214 respondents not being offered the first five questions on the survey due to an error 
in skip logic.  A problem with the way the electronic administration prompted for responses to 
questions left blank may have added to the number of individuals not responding to the complete 
survey.  Item one of the on-line surveys was the eligibility screening question, and items 2-26 
were the TRSC.  One hundred and ninety-five individuals provided answers to at least 15 of the 
first 25 items (the entire TRSC).  Employment of a mean scale score enabled the use of the 
responses from all 195 subjects for the TRSC.  The decision to use a mean scale score was 
verified by Levene’s test and a t-test, both of which demonstrated no significant differences 
between the scores of those who had missing data and those respondents who had no missing 
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data.  One-hundred and seventy-five subjects provided sufficient data for the DARS and 
HRQOL-LASA, as well as for the Subject Characteristics and Health Form.  Subject 
characteristics and health information were the most often missed items, perhaps due to the 
sensitive nature of the questions and the fact that they came at the end of the survey.  There were 
40 participants who had nearly complete data and 135 individuals who had complete data, for a 
total of 175 providing sufficient subject characteristics and health information for analysis for the 
final three portions (DARS, HRQOL-LASA, Subject Characteristics and Health Form) of the on-
line survey.  
 Originally, the survey instrument was designed by the researcher as one continuous 
document with a button at the end following item 50 that allowed the study participant to submit 
results.  The Webmaster consultant advised that it would be frustrating to the subjects to need to 
return scroll through multiple screens to fill in missing items.  The on-line survey was adapted in 
such a manner that page breaks were determined based on what was visible on a single screen.  
After participants finished each survey page, any item(s) left blank were marked with an asterisk 
as mandatory, and respondents were prompted to complete the items marked by the asterisk 
before moving from the page.  This was designed for ease of review, but also apparently 
contributed to a tendency for the respondents to quit the entire survey at the end of a page rather 
than respond to the prompts to fill in items left blank. 
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Chapter IV 
Results 
The purpose of this study was to explore how breast cancer survivors described their 
treatment experience and how their symptom management was impacted through the presence or 
absence of the BDNF Val66Met SNP.  The results obtained were significant in several areas, 
from both Phase 1 and Phase 2.  This chapter presents the results of the study, including the 
subject characteristics and the findings for each research question.  
The primary aim of the study was to examine the relationship between self-reported 
symptom occurrence and severity, as measured by the Therapy-Related Symptom Checklist 
(TRSC) total scores, and the presence or absence of the BDNF Val66Met SNP in breast cancer 
survivors. The primary research question (RQ) was as follows: Is there a significant relationship 
between symptom occurrence and severity in breast cancer survivors and the presence or absence 
of the BDNF Val66Met SNP?  Secondary RQs included the following: (a) What are the 
occurrence and severity of symptoms among breast cancer survivors as reported on the TRSC 
after the completion of their cancer therapy regimen? (b) Are there significant relationships 
among symptom occurrence and severity, daily activities ratings, and health-related quality of 
life and selected demographic and other variables (age, ethnicity, education, type of treatment, 
and time since completion of treatment)? and (c) What self-care methods are used by survivors 
to alleviate symptoms, and what are the survivors’ perceptions of the usefulness of these self-
care methods?  
Sample – Phase 1 
 The sample size for Phase 1 analysis varied for several reasons, as described in Chapter 
3.  The overall sample for Phase 1 originally consisted of 214 individuals who completed at least 
some of the 50 items of the on-line survey.  Of these 214 respondents, 195 completed sufficient 
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responses (15 out of 25) to compute a mean scale score for the TRSC, and 175 of these also 
provided subject characteristics and health information. 
Sample Demographics 
Sample demographics for the Phase 1 subjects are provided in Table 4. 
Table 4 
Sample Characteristics – Phase1 and Phase 2 
____________________________________________________________________________________________________ 
Variables   Categories     Phase 1 subjects             Phase 2 subjects 
                                                     (N = 175)
a
     High TRSC        Low TRSC 
                                                                                     (f
b
, %)            (n = 26)             (n = 25)  _     
Age groups 
   ≤50 years          48 (27.4) 9 (36.4)      4 (16.0)    
   51-60 years            68 (38.9)        10(38.5)        12 (48.0) 
       ≥61 years                       59 (33.7)         7 (26.9)           9 (36.0) 
Ethnic background   
   White                                   162 (92.6)        25 (96.2)          25 (100.0) 
   African American/Black        6 (3.4)             1 (3.8)         0 (0.0) 
   Asian                                       2 (1.1)             0 (0.0)        0 (0.0) 
   Hispanic                                  3 (1.7)             0 (0.0)        0 (0.0) 
                         Other                                       2 (1.1)              0 (0.0)         0 (0.0) 
Years of education 
   High school                            42 (24.0)        9 (34.6)           2 (8.0) 
   Vocational/Associate’s  
                                         degree         30 (17.1)         6 (23.1)           2 (8.0) 
                         Bachelor’s degree                   49 (28.0)          7 (26.9)           11 (44.0) 
   Master’s/Graduate degree       54 (30.9)         4 (15.4)           10 (40.0) 
Treatment 
   Surgery only                            24 (13.7)      0 (0.0)     5 (20.0) 
   Radiation only             5 (2.9)            0 (0.0)          1 (4.0) 
   Surgery/chemotherapy 38 (21.7)         7 (26.9)            7 (28.0) 
   Surgery/radiation                   27 (15.4)         1 (3.8)             8 (32.0) 
   Surgery/chemo/radiation        81 (46.3)         18 (69.2)          4 (16.0) 
Completed treatment 
   ≤ 2 years   42 (26.9)          6 (23.1)          6 (24.0) 
   3-4 years   59 (33.7)         10 (38.5)          8 (32.0) 
                 ≥5 years   69 (39.4)          9 (34.6)           11 (44.0) 
   Missing                                    0 (0.0)             1 (3.8)             0 (0.0) 
                   
           (continued) 
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____________________________________________________________________________________________________ 
Variables   Categories     Phase 1 subjects             Phase 2 subjects 
                                                     (N = 175)
a
     High TRSC        Low TRSC 
                                                                                     (f
b
, %)            (n = 26)             (n = 25)  _     
Primary caregiver 
   Self     71 (40.6)         10 (38.5)        12 (48.0) 
   Spouse    36 (20.6)         9 (34.6)            4 (16.0) 
   Other    4 (2.3)            0 (0.0)             1 (4.0) 
   Self/spouse              40 (22.9)          2 (7.7)              4 (16.0) 
   Self/other              9 (5.1)              2 (7.7)             3 (12.0) 
   Spouse/other              4 (2.3)             1 (3.8)             1 (4.0) 
   Self/spouse/other  11 (6.3)            2 (7.7)              0 (0.0) 
Children living at  
home 
   No children                       120 (69.4)   18 (69.2)         20 (80.0) 
   <6 years                                   6 (3.5)        1 (3.8)             2 (8.0) 
   7-17 years                             20 (11.6)         1 (3.8)           2 (8.0) 
   18-26 years                             15 (8.7)           2 (7.7)             1 (4.0) 
       >26 years                             4 (2.3)             1 (3.8)             0 (0.0) 
   <6  and 7-17 years                3 (1.7)              2 (7.7)             0 (0.0) 
   7-17 and 18-26 years             3 (1.7)              1 (3.8)              0 (0.0) 
   7-17 and >26 years              1 (0.6)              0 (0.0)             0 (0.0) 
   18-26 and >26 years             1 (0.6)              0 (0.0)             0 (0.0) 
Other conditions 
   If yes, please specify           0 (0.0)              0 (0.0)            8 (32.0) 
                                    Yes                               68 (39.1)         6 (23.1)           0 (0.0) 
   No                                        106 (60.9)        20 (76.9)         17 (68.0) 
Taking medications  
(OTC, herbals,  
prescriptions, etc.) 
   If yes, please specify             0 (0.0)            21 (80.8)        19 (76.0) 
        Yes                147 (84.5)        2 (7.7)              1 (4.0) 
   No                                           27 (15.5)          2 (7.7)             5 (20.0)    _             
a
Twenty of the individuals who responded to the TRSC did not provide demographic 
information.   
b
The symbol f stands for frequency. 
 
The overwhelming majority of the 175 participants who provided demographic and 
health information were Caucasian (92.6 %), as compared to the population of the state in which 
the preponderance of the study participants resided, which was 69% Caucasian, according to the 
U.S. census data (U.S. Census Bureau, 2010).  Nearly all of the study participants had surgery as 
part of their treatment (92.1%).  Almost three fourths of the Phase 1 subjects (72.6%) were over 
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50 years old.  The respondents were highly educated; 58.9% held a bachelor’s degree or higher, 
and an additional 17.1% had vocational training or an associate’s degree.  A great number of the 
subjects (73.1%) were three or more years post-treatment and had no other conditions that they 
felt contributed to symptoms (60.9%). Eighty-four percent of subjects reported taking some type 
of medication; the survey did not include a question about the frequency of the medication.  
Sample - Phase 2 
  A purposive subsample of 51 Phase 1 participants was chosen for Phase 2 of the study. 
The subsample of Phase 2 subjects did not reflect any selection biases regarding age, ethnicity, 
or education.  The descriptive statistics profile did not vary from the Phase 1 sample (see Table 
1).  
Reliability and Validity Assessment 
 Internal consistency reliability was investigated based on the data from all self-report 
instruments.  The instruments in this study demonstrated internal consistency reliability as 
evidenced by acceptable Cronbach’s alpha levels: the TRSC at 0.91, the DARS at 0.70, the 
HRQOL-LASA at 0.93, and the SA: SCM at 0.89.  Information substantiating validity was 
included in Chapters 2 and 3. 
Primary Research Question 
The primary research question for this study was as follows: Is there a significant 
relationship between symptom occurrence and severity in breast cancer survivors and the 
presence or absence of the BDNF Val66Met SNP?   
Association Between BDNF and TRSC Scores (Phase 2 Data) 
Initially, no potential confounders were controlled for in the analysis.  In the Phase 2 
(enriched) sample, 36% (9 out of 25) of the subjects with a low TRSC score had the Val66Met 
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SNP, which would be expected in a healthy control sample.  In contrast, only 7.7% (2 out of 26) 
of the subjects with high TRSC scores had the Val66Met SNP.  Eight or nine subjects with the 
Met variant would have been expected to align with the one third that is common in healthy 
controls.  In this sample, before adjusting for potential confounders, the presence of the BDNF 
Val66 Met SNP variant was significantly associated with low TRSC scores (odds ratio, OR = 
0.148; 95% confidence interval (CI [0.028, 0.78]; Fisher’s p = 0.019).  This means the odds that 
a subject with the variant has a high TRSC score was 85% lower than the odds for a subject 
without the variant, ([0.148-1] x 100 = -85%).  The association (lower TRSC scores were related 
to the presence of the BDNF Val66Met SNP or variant, and higher scores were related to the 
absence of the variant) was in the opposite direction of what was originally expected based on 
the literature reviewed. 
 A possible explanation for these unexpected results was explored.  The BDNF literature 
has suggested that certain biobehavioral symptoms may be more sensitive to the presence or 
absence of the BDNF variant.  The four biobehavioral symptoms included in the TRSC (feeling 
sluggish, difficulty concentrating, depression, and difficulty sleeping) were considered in a 
subanalysis to explore further possible relationships between the BDNF variant and TRSC 
symptom ratings.  There were some problems in this approach as the purposive sample design 
was predicated on the complete TRSC score and not the subscale, but the exploration proceeded 
with the realization that the violation of the design would need to be taken into consideration.  
However, there was no relationship demonstrated between the score from four symptoms listed 
above and the presence or absence of the variant.  Consequently, further research is needed to 
replicate and explain these findings.  The frequencies for the sum of the scores for question 14 
(feeling sluggish), question 15 (depression), question 16 (difficulty concentrating), and question 
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23 (difficulty sleeping) were examined.  A cutoff score of 7 (a score of 0-7 indicated a low score, 
while 8-14 indicated a high score) was chosen for the purpose of analysis.  The results were not 
significant: There is no relationship demonstrated between the score from these four symptoms 
and the presence or absence of the variant. 
Adjustment for Possible Confounders 
Logistic regression was conducted to investigate the association between the BDNF 
Val66Met SNP variant and TRSC scores.  To control for potential confounders, the Phase 2 
(enriched) sample of high-scoring (> 23, n = 26) and low-scoring (< 14, n = 25) subjects was 
used.  A stepwise selection procedure was used to build a logistic regression model of high 
TRSC scores.  The variable BDNF was forced to remain in the model during the selection 
procedure regardless of its degree of statistical significance.  Information concerning the final 
model is in Table 5.  The potential independent variables investigated were age, education, type 
of treatment, and time since treatment completion.  Ethnicity was not included as there was only 
one nonwhite subject (1 out of 51).  Only two variables were significantly associated with high 
TRSC scores: treatment type (defined as chemotherapy versus no chemotherapy) and education 
(defined as high level, bachelor’s degree or higher, versus low level, less than a bachelor’s 
degree).  After adjusting for treatment type and education, the BDNF genotype did not have a 
significant effect on high TRSC scores (OR = 0.27; 95% CI, [0.036, 1.98]; p = 0.196).  Thus, 
after adjusting for confounders, the odds that a subject with the variant has high TRSC score was 
73% lower than the odds for a subject without the variant, ([0.27-1] x 100= -73%); however, this 
reduction in the odds was not statistically significant.  With the small sample, power was an 
issue. 
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Table 5 
Final Logistic Regression Model of High TRSC Scores in Phase 2 (Enriched) Breast Cancer 
Survivor Sample That Included Only Subjects with High Scores (≥ 23, n = 26) and Subjects with 
Low Scores (≤ 14, n = 25) 
____________________________________________________________________________ 
Variable         Odds ratios       95% CI lower   95% CI upper    p value         _   
 
Val66Met SNP present                0.27              0.036         1.981          0.196 
 
Chemotherapy included as               29.29               2.812              305.096           0.005 
part of treatment 
 
High level of education                    0.14                 0.025               0.798             0.027 
(bachelor’s degree  
and higher)                                                                                                                                     _ 
Note. The Hosmer and Lemeshow Goodness of Fit Test results (Chi-square = 2.4, p = .662) 
provided evidence that the model fit well. 
 
Table 5 also shows the sizes of the effects (odds ratios) of treatment type and education 
on the odds of having a high TRSC score. After adjusting for education and BDNF genotype, the 
odds of having a high TRSC score were significantly and substantially increased (almost by 
3000%) if the type of treatment included chemotherapy (OR = 29.29, p = 0.005). After adjusting 
for treatment type and BDNF genotype, the odds of having a high TRSC score were 86% lower 
in subjects with a high education level (OR = 0.14, p = 0 .027). 
Secondary Research Questions 
Three secondary research questions were addressed by this study.  Each question will be 
discussed in a separate section, but tables and information presented in one section may have a 
bearing on the other questions. 
First Secondary Research Question 
 The first secondary research question was as follows: What is the occurrence and severity 
of symptoms among breast cancer survivors as reported on the TRSC after the completion of 
their cancer therapy regimen?  Table 6 shows the symptom occurrence and severity as measured 
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by the TRSC for the Phase 1 sample.  Note that Table 6 and several other tables reflect the 
fourteen subscales of the TRSC.  
Table 6 
TRSC Scores of Phase 1 Subjects - Percent Distributions on Symptom Severity and on Symptom 
Occurrence (N =195) 
________________________________________________________________________________________________ 
                          Degree of Severityc 
TRSC symptom items                  0            1         2       3        4      Mean        Percent       Total 
by subscales/clusters                                                         Severity   Occurrence      N  
1. Fatiguea 
    Feeling sluggish    41 (21.0)       63 (32.3)      62 (31.8)     21(10.8)     8 (4.1)       1.45            79.0        195 
    Depression                      74 (37.9)      71(36.4)      38 (19.5)    11 (5.6)     1 (0.5)      0.94           62.1  195 
    Difficulty  
    concentrating     56 (28.7)      69 (35.4)     56 (28.7)    11 (5.6)     3 (1.5)      1.16           71.3 195 
    Difficulty sleeping           55 (30.1)      41 (22.4)     63 (34.4)    19 (10.4)   5 (2.7)      1.33           69.9 183 
2. Eatinga 
    Taste change                    73 (52.1)     25 (17.9)     31 (22.1)     9 (6.4)       2 (1.4)       0.87          47.9    140 
    Loss of appetite               85 (60.7)     25 (17.9)     26 (18.6)     4 (2.9)       0 (0.0)       0.64          39.3   140 
    Weight loss     106 (75.7)   20 (14.3)     14 (10.0)     0 (0.0)       0 (0.0)       0.34          24.3         140 
    Difficulty swallowing     161 (82.6)   25 (12.8)     8 (4.1)         1 (0.5)       0 (0.0)       0.23          17.4 195 
3. Oropharyngeala  
    Sore mouth                      143 (73.3)   24 (12.3)     23 (11.8)     4 (2.1)       1 (0.5)       0.44          26.7   195 
    Sore throat                        169 (86.7)   22 (11.3)     3 (1.5)         1 (0.5)       0 (0.0)       0.16          13.3     195 
    Jaw pain                            179 (91.8)   10 (5.1)       6 (3.1)         0 (0.0)       0 (0.0)       0.11          8.2   195 
4. Nauseaa     
    Nausea                             81 (57.9)     35 (25.0)     18 (12.9)     5 (3.6)       1 (0.7)       0.64          42.1   140 
    Vomiting                           113 (80.7)   17 (12.1)     7 (5.0)         2 (1.4)       1 (0.7)       0.29          19.3 140 
5. Fevera  
    Fever                                161 (84.3)    25 (13.1)     4 (2.1)        1 (0.5)        0 (0.0)      0.19           15.7 191 
    Bruising                            133 (69.6)    40 (20.9)     16 (8.4)      2 (1.0)        0 (0.0)      0.41           30.4 191 
6. Respiratorya 
    Cough                               162 (83.1)   27 (13.8)      6 (3.1)         0 (0.0)       0 (0.0)      0.20           16.9    195 
    Shortness of breath          132 (67.7)   48 (24.6)      14 (7.2)       0 (0.0)       1 (0.5)      0.41           32.3 195 
7. Painb                                79 (43.2)     47 (25.7)      44 (24.0)     8 (4.4)       5 (2.7)      0.98           56.8 183 
8. Numbness in  
fingers and/or toes b            100 (51.3)   43 (22.1)     36 (18.5)     15 (7.7)      1 (0.5)      0.84           48.7   195 
9. Bleedingb                          167 (87.4)   18 (9.4)       5 (2.6)         1 (0.5)        0 (0.0)      0.16           12.6 191 
10. Hair lossb                         83 (43.5)     24 (12.6)     8 (4.2)         28 (14.7)    48 (25.1) 1.65            56.5 191 
11. Skin changesb                  72 (37.7)     58 (30.4)     55 (28.8)     3 (1.6)        3 (1.6)      0.99           62.3   191 
12. Constipationb                   90 (49.2)     34 (18.6)    42 (23.0)     13 (7.1)      4 (2.2)      0.95           50.8 183 
13. Soreness in veinb             144 (78.7)   28 (15.3)     7 (3.8)         4 (2.2)        0 (0.0)      0.30           21.3   183 
14. Decreased interest  
      in sexual activityb            50 (27.3)      43 (23.5)     40 (21.9)    34 (18.6)    16 (8.7)   1.58            72.7  183 
a
TRSC multiple item subscales/clusters. 
b
TRSC single item subscale.  
c
TRSC rating: O = None/No Symptom;1 = Mild; 2 = Moderate; 3 = Severe; 4 = Very Severe. 
 
Feeling sluggish was the most commonly occurring symptom, with 79% of Phase 1 
subjects indicating that they had a problem with this symptom.  The other three symptoms in the 
 
 
66 
 
Fatigue symptom cluster were rated in the top six in terms of occurrence (difficulty 
concentrating, 71%, difficulty sleeping, 70%, depression, 62%).  It is noted that 40% or more 
(range 42.1% to 79%) reported the occurrence of 11 TRSC symptoms on the 25-item checklist. 
The least frequently reported symptoms was jaw pain at 8%, and it also had the lowest mean 
severity score at 0.11.  Hair loss had the highest mean severity score (1.65).  Table 7 shows the 
occurrence and percent distribution by severity of TRSC scores for Phase 2 participants based on 
their whether the Val66Met SNP was present or absent.  
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Table 7 
Phase 2 TRSC Scores - Present Versus Absent BDNF SNP and Percent Distributions on Symptom Severityc and on 
Symptom Occurrence (n = 51) 
__________________________________________________________________________________________________ 
         Val/Val (BDNF SNP absent) (n = 40)           Val/Met or Met/Met present (n = 11) 
TRSC total score and    0        1        2        3       4      Meand     %            0        1       2        3      4   Meand      % 
items by symptoms/                                                          Severity  Occur                                               Severity Occur                           
subscales                                                                                                                                       _                      
1. Fatiguea 
    Feeling sluggish     15.0   27.5   35.0   15.0   7.5    1.73     85.0         36.4    45.5   0.0     18.2   0.0   1.00   63.6  
    Depression                     27.5   35.0   30.0   5.0     2.5    1.20     72.5         45.5    36.4   18.2   0.0     0.0   0.73   54.5 
    Difficulty concentrating 12.5   42.5   32.5   10.0    2.5    1.47     87.5         36.4    36.4   27.3   0.0     0.0   0.91  63.6 
    Difficulty sleeping          30.0   15.0   40.0   7.5     7.5    1.48     70.0         36.4    18.2   36.4   9.1     0.0   1.18   63.6 
2. Eatinga 
    Taste change                   43.2   18.9   24.3   8.1     5.4    1.14     56.8         80.0    0.0     10.0   10.0   0.0   0.50   20.0 
    Loss of appetite              45.9   27.0   24.3   2.7     0.0    0.84     54.1         80.0    0.0     10.0   10.0   0.0   0.50   20.0 
    Weight loss                     70.3   18.9   10.8   0.0     0.0    0.41     29.7         70.0    30.0   0.0     0.0     0.0   0.30   30.0        
    Difficulty swallowing     80.0   12.5   5.0     2.5     0.0    0.30     20.0         100.0  0.0     0.0     0.0     0.0   0.0     0.0 
3. Oropharyngeala 
    Sore mouth                   72.5   12.5   12.5   2.5     0.0    0.45     27.5         81.8    18.2   0.0     0.0     0.0   0.18   18.2 
    Sore throat                   87.5   10.0   0.0     2.5     0.0    0.18     12.5         81.8    18.2   0.0     0.0     0.0   0.18   18.2 
    Jaw pain                          87.5   10.0   2.5     0.0     0.0    0.15     12.5         90.9    0.0     9.1     0.0     0.0   0.18   9.1 
4. Nauseaa 
    Nausea                            43.2   27.0   21.6   8.1     0.0    0.95     56.8         80.0    10.0   10.0   0.0     0.0   0.30   20.0 
    Vomiting                         73.0   13.5   10.8   2.7     0.0    0.43     27.0         80.0    10.0   10.0   0.0     0.0   0.30   20.0 
5. Fevera  
    Fever                               80.0   17.5   2.5     0.0     0.0    0.23     20.0         100.0  0.0     0.0     0.0     0.0   0.0     0.0 
    Bruising                          60.0   27.5   12.5   0.0     0.0    0.53     40.0         90.9    0.0     9.1     0.0     0.0   0.18   9.1 
6. Respiratorya 
    Cough                             82.5   17.5   0.0     0.0     0.0    0.18     17.5         90.9    9.1     0.0     0.0     0.0   0.09   9.1 
    Shortness of breath         62.5   30.0   7.5     0.0     0.0    0.45     37.5         72.7    27.3   0.0     0.0     0.0   0.27   27.3 
7. Painb                               37.5   20.0   40.0   2.5     0.0    1.07     62.5         36.4    36.4   18.2   9.1     0.0   1.00   63.6 
8. Numbness in  
    fingers and/or toesb         50.0   17.5   22.5   10.0   0.0    0.93     50.0         54.5    18.2   9.1     9.1     9.1   1.00   45.5 
9. Bleedingb                        85.0   15.0   0.0     0.0     0.0    0.15     15.0         90.9    9.1     0.0     0.0     0.0   0.09   9.1 
10. Hair lossb                     27.5   20.0   2.5     17.5   32.5  2.07     72.5         81.8    0.0     0.0     0.0     18.2 0.73   18.2 
11. Skin Changesb              30.0   37.5   30.0   0.0     2.5    1.08     70.0         72.7    18.2   9.1     0.0     0.0   0.36   27.3 
12. Constipationb                47.5   17.5   22.5   10.0   2.5    1.02     52.5         63.6    18.2   18.2   0.0     0.0   0.55   36.4 
13. Soreness in veinb          72.5   20.0   2.5     5.0     0.0    0.40     27.5         90.9    0.0     9.1     0.0     0.0   0.18   9.1 
14. Decreased interest  
      in sexual activityb          17.5   25.0   22.5   25.0   10.0  1.85     82.5         45.5    18.2    18.2   9.1     9.1   1.18  54.5 
aTRSC multiple item subscales/clusters. 
bTRSC single item subscale.  
c
TRSC rating: O = None/No Symptom;1 = Mild; 2 = Moderate; 3 = Severe; 4 = Very Severe
 
dMeans were calculated in a restricted or “enriched” sample.  
 
 In Table 7, a pattern emerged that (compared to the “present” group, which reported low 
occurrence) the “absent” BDNF SNP group showed that 50% or more of the subjects (range 
51.3% to 87.2%) reported the occurrence of 12 TRSC symptoms on the 25-item checklist (four 
symptoms were on the Fatigue subscale; two on the Eating subscale; one on the Nausea subscale; 
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and one each on the single-item subscales of Pain, Numbness, Hair Loss, Skin changes, 
Decreased Interest in Sexual Activity, and Constipation).  Moreover, in the absent group, higher 
mean severity (range 2.10 to 1.00) on those symptoms was reported.  It is important to note that 
this mean value included those with 0 values (no symptoms).  Thus, if the mean severity 
calculations included only those who experienced the symptom, the mean severity for that 
symptom would be one point higher, reflecting moderate to severe mean severity on the TRSC. 
Power is an issue due to the low number of survivors who had the Met allele. 
To further explore the results in Table 7, two significant variables (chemotherapy use and 
education) were considered along with the gene variant.  Table 8 illustrates the relationship in the 
Phase 2 subjects regarding chemotherapy use, BDNF presence or absence, and TRSC scores.  
This descriptive analysis was based on the purposive sample of 51 Phase 2 subjects, as described 
in Methods.  In the present exploratory analysis, TRSC scores greater than 23 were high scores; 
scores less than 23 were low scores. 
Table 8 
 
 Frequency and Percentage of Phase 2 Subjects Having a High TRSC Score (> 23) Based on 
Treatment Type and Presence or Absence of BDNF Val66Met SNP (n = 51) 
 
 BDNF Val66Met SNP present BDNF Val66Met SNP absent 
Chemotherapy as part of 
treatment 
2/5 (40%) 23/31 (74%) 
No chemotherapy as part of 
treatment 
0/6 (0%) 1/9 (11%) 
 
 Each cell illustrates the proportion of high TRSC scores as designated by the column and 
row headings.  For example, cell 1.1 displays the results for the number of survivors who would 
simultaneously have the variant, had chemotherapy as part of their treatment, and earned a high 
TRSC score.  Thus, referring to Table 7 for all the specific symptoms, Table 8 shows that 74% of 
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subjects with high symptom occurrence and severity on the TRSC were on chemotherapy and 
had an absent BDNF Val66Met SNP.  
 Table 9 shows Phase 2 subjects and the relationships among education, BDNF presence 
or absence, and high TRSC scores.  
Table 9 
Frequency and Percentage of Phase 2 Subjects Having a High TRSC Score (> 23) Based on 
Education Level and Presence or Absence of BDNF Val66Met SNP (n = 51) 
 
 BDNF Val66Met SNP present BDNF Val66Met SNP absent 
High level of education 1/9 (11%) 10/23 (43%) 
Low level of education 1/2 (50%) 14/17 (85%) 
  
 The highest proportion of survivors as illustrated in the table is in cell 2.2.  The values 
include the survivors who would simultaneously not have the variant, held less than a bachelor’s 
degree, and earned a high TRSC score.  Again, referring to Table 7, Table 9 shows that 85% of 
subjects with high symptom occurrence and severity on the TRSC had low education levels and 
absent BDNF Val66Met SNP.  
  Second Secondary Research Question 
 The second secondary research question was as follows: Are there significant 
relationships among symptom occurrence and severity, daily activities ratings, and health-related 
quality of life and selected demographic and other variables (age, ethnicity, education, treatment 
method, and time since treatment)?   This question was addressed using correlation and 
regression.  
 Relationships between the instruments.  Since the DARS and the HRQOL-LASA are 
moderately correlated (Pearson’s r = -0.42; p < 0.001), they were not included together in linear 
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regression models due to potential colinearity problems.  Linear regression was conducted to 
assess whether the DARS or HRQOL-LASA were associated with TRSC score.   
 Health-related quality of life.  Only HRQOL-LASA (p < 0.001) and chemotherapy (p < 
0.001) have a significant relationship with TRSC. Table 10 displays the final model.  
Table 10 
Regression Coefficients of Final Linear Model of TRSC Scores –Not Including DARS (N = 175)  
______________________________________________________________________________ 
Variable                         Regression                 95% CI lower          95% CI upper           p value 
                                       coefficient
a 
                                                                                                _     
HRQOL-LASA
b
                 -0.114                           -0.154                    -0.075                 <0.001 
 
Chemotherapy                    0.393                             0.261                     0.526                 <0.001 
   included as  
   part of treatment                                                                                                                           _ 
Note.
 
The model was built using a backward selection procedure that did not include the DARS 
in the initial set of investigated independent variables. 
a
Regression coefficients are unstandardized B.    
b
Health-Related Quality of Life – Linear Analog Self-Assessment (HRQOL-LASA).                                                                                                                           
 Health-related quality of life-linear analogue scale assessment (HR-QOL).  Table 10 
shows that, after adjusting for chemotherapy, a one unit increase in the quality of life score was 
significantly associated with a reduction of 0.114 in the TRSC score, 95% CI [-0.154, -0.075]. 
After adjusting for quality of life, the mean TRSC score for the group of subjects who reported 
receiving chemotherapy was increased by 0.393, compared to the group who did not receive 
chemotherapy as a part of their treatment regimen.  After adjusting for both quality of life and 
chemotherapy, the variables of age, education, and time since treatment were not significantly 
associated with TRSC scores, and they were eliminated from the final model.  Additional 
analyses showed that conclusions were essentially the same when all categories of age, 
education, and time were included in the regression model in place of the dichotomized 
variables. 
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 Daily activities.  Only the DARS (p < 0.001), chemotherapy (p < 0.001), and age (p = 
0.007) were significantly associated with the TRSC.  Table 11 displays the model coefficients. 
Table 11 
 
Regression Coefficients of Final Linear Model of TRSC Scores – Not Including HRQOL-LASA 
(N =175)  
______________________________________________________________________________ 
Variable                         Regression
a
                 95% CI lower          95% CI upper           p value 
                                       coefficient                                                                                                 _     
DARS
b
                              0.102                      0.069                      0.134                 <0.001   
 
Chemotherapy                   0.382                             0.252                      0.512                  <0.001 
   included as  
   part of treatment  
Age
c
                                -0.106                           -0.183                     -0.029                  0.007      
Note. The model was built using backward selection procedure that did not include the HRQOL-
LASA in the initial set of investigated independent variables (N = 175). 
a
Regression coefficients are unstandardized B. 
b
Daily Activities Rating Scale (DARS).
 
c
Age was a dichotomized variable with individuals above and below 50 years old.                                 
 
 After adjusting for chemotherapy treatment and age, a 1-unit increase in the Daily 
Activities Rating Scale (DARS) score was significantly associated with an increase of 0.102 in 
TRSC score, 95% CI [0.069, 0.34].  See Table 11 for details.  After adjusting for daily activities 
and age, the mean TRSC score for the group of subjects who reported receiving chemotherapy 
increased by 0.382, compared to the group who did not receive chemotherapy as a part of their 
treatment regimen, 95% CI [0.252, 0.512].  Furthermore, after adjusting for chemotherapy and 
daily activities, older subjects had a reduction of their TRSC score of 0.106 as compared to the 
younger subjects (see Table 11).  The results obtained after adjusting for daily activities, age, and 
chemotherapy revealed that education and time since treatment were not significantly associated 
with TRSC scores, and they were dropped from the final model (see Table 11). 
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Third Secondary Research Question 
 The third secondary research question was as follows: What self-care methods are used 
by survivors to alleviate symptoms, and what are the survivors’ perceptions of the usefulness of 
these self-care methods?  This question was addressed by descriptive statistics and content 
analysis according to standard guidelines for organizing according to themes and concepts 
(Krippendorf, 2004; P. D. Williams et al., 2009; 2010 a, b).  The categories of self-care 
established in the studies of P. D. Williams et al. (2006; 2010 a, b) were used: (a) 
diet/nutrition/lifestyle, (b) mind/body control, (c) herbs vitamins/complementary therapies, (d) 
medication, (e) other, and (f) doing nothing.  The diet/nutrition/lifestyle categories included such 
self-care actions as reading to alleviate difficulty sleeping, eating fiber for constipation, and 
playing tennis to cope with depression.  The mind/body control category included “working 
through it” to alleviate depression, “pretend I was interested” for the symptom of decreased 
interest in sexual activity, and “listening to music” that one participant listed as the alleviation 
method for each of the symptoms she rated.  Herbs/vitamins/complementary therapies included 
such methods as acupuncture (one subject) and sesame oil.  The medication category included 
both prescription and over-the-counter drugs.  The “other” category seemed to collect very 
symptom-specific interventions, such as the use of lotions for skin changes or going to a 
physician specialist that related to the particular symptom.  “Doing nothing” was the most 
frequent response for six of the symptoms.  Table 12 lists the frequency of use of the six 
categories of self-care methods that were utilized by survivors to alleviate symptoms as grouped 
in the subscales. 
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Table 12 
 
Frequencies of Symptom Alleviation: Self-care Methods (SA: SCM) by Categories (n = 51) 
_____________________________________________________________________________________________ 
                                                                                                Self-care categoriesa                                        Rank of most often 
A B C D E F         reported self-care  
TRSC items by symptomsubscales/clusters                                                 for symptoms_         
1. Fatigued 
    Feeling sluggish      30f 4 2 4 0 7  1 
    Depression    7 14 0 11 4 6 
    Difficulty concentrating   14 8 0 3 2 18k  4b 
    Difficulty sleeping   8 4 1 15 0 10 
2. Eatingd 
    Taste change    17f 0 0 2 0 5  5c  
    Loss of appetite   10 0 0 1 0 10 
    Weight loss    4 0 0 0 0 9    
    Difficulty swallowing   1 0 0 1 1 5 
3. Oropharynxd 
    Sore mouth    3 0 0 4 3 3 
    Sore throat    3 0 0 2 0 3  
    Jaw pain    2 0 0 0 1 3 
4. Nausead 
    Nausea    8 0 1 18g 2 1                            4b 
    Vomiting      1 1 0 6 1 2                       
5. Feverd 
    Fever     0 0 0 5 0 3 
    Bruising    3 0 1 1 0 12 
6. Respiratoryd 
    Cough    3 0 0 1 1 3 
    Shortness of breath   6 4 0 1 0 8 
7. Paine     6 0 2 25g 2 3  2  
8. Numbness in fingers and/or toese  6 0 2 5 3 10 
9. Bleedinge    1 0 0 0 1 5 
10. Hair losse    14 1 0 1 2 15 
11. Skin changese    3 0 2 5 17h 8  5c 
12. Constipatione    7 0 0 12 1 3 
13. Soreness in veine   0 0 0 1 3 7 
14. Decreased interest in sexual activitye 1 7 0 4 2 24k  3          _ 
a Self-care categories: A. Diet/nutrition/lifestyle; B. Mind/body control; C. Herbs/vitamins/complementary therapy ; 
D. Medications; E. Other, and F. Do nothing.                                 
b,cThese items were tied in the ranking.  
dTRSC multiple item subscales/clusters. 
eTRSC single item subscale. 
f  “Diet/nutrition/lifestyle” was most frequently used for Feeling Sluggish and Taste Change 
g “Medications” were most frequently used for Nausea and Pain 
h “Other” self –care alleviation methods (usually lotion) were most often used for Skin changes 
k “Do nothing” was the most common response for Difficulty concentrating and Decreased interest in sexual activity 
 
    
 The subjects could identify more than one symptom alleviation method per symptom. 
The top-ranked symptom alleviation method category used was diet/nutrition/lifestyle for the 
symptom of depression (30 subjects out of 47 used self-care for this symptom).  Second-ranked 
 
 
74 
 
was the medications category for pain (25 out of 38).  In third place was “do nothing” (24 out of 
38) for decreased interest in sexual activity.  Tied for the fourth most common alleviation 
method, with 18 responses each, was “do nothing” for difficulty concentrating (18 out of 45) and 
medications for nausea (18 out of 30).  Seventeen responses each earned a tied ranking for fifth 
place for the diet/nutrition/lifestyle category for the taste change symptom (17 responses out of 
24) and “other” (most often some version of applying lotion or moisturizer) for skin changes (17 
responses out of 35). 
 “Medication” was the leading alleviation method for difficulty sleeping (39% of the 
responses).  Herbs/vitamins/complementary therapy was the least often used category of any 
alleviation method with only one or two subjects indicating that they used that alleviation 
method for each of seven symptoms (two subjects listed feeling sluggish, 4%; two listed pain, 
5%; two listed numbness in fingers and toes, 8%; two listed skin changes, 6%; one listed 
difficulty sleeping, 3%; one listed nausea, 3%; and one listed bruising, 6%). 
 Biobehavioral Symptom Cluster.  The biobehavioral TRSC symptom cluster of Fatigue 
includes four symptoms (feeling sluggish, depression, difficulty concentrating, difficulty 
sleeping).  The most common and highest rated alleviation methods for feeling sluggish were in 
the diet/nutrition/lifestyle category, with “rest” and “exercise” listed as frequent responses.  This 
also was the symptom for which the greatest number of responses for alleviation methods was 
reported.  For depression, mind/body control techniques, such as “remaining positive” or 
“prayer,” were the most common, with “medications” as a close second.  For difficulty 
concentrating, the most common response was “do nothing” (40% of the responses), with 
lifestyle changes, such as “making a list,” the next most frequent at 31% of the responses for that 
symptom.  As mentioned, “medication” was often used for difficulty sleeping. 
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 Table 13 displays the frequency of survivors’ use of self-care methods in four categories, 
from the lowest frequency category (seldom done) to the highest frequency category (very often 
done).  For each symptom, the table illustrates survivors’ perceptions of the usefulness of 
whatever self-care method(s) they chose, as indicated by a positive response to the survey 
question, “Did it help?” 
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Table 13 
Frequencies of Symptom Alleviation Occurrence and Usefulness (n = 51) 
_________________________________________________________________________  
Alleviation occurrence
a
     Helped   
                   1 2 3 4               alleviate 
1. Fatigue
b
 
    Feeling sluggish      0 5 18 8  27 (87.1%)   
    Depression    0 4 11 12  25 (92.6%)   
    Difficulty concentrating  0 4 10 7  19 (90.5%)   
    Difficulty sleeping   0 4 5 12  20 (95.2%)   
2. Eating
b
 
    Taste change   1 1 7 10  18 (94.7%)   
    Loss of appetite   1 1 5 3  8 (88.9%)  
    Weight loss    0 1 1 2  2 (50.0%)   
    Difficulty swallowing  0 1 0 2  2 (100.0%)   
3. Oropharynx
b
 
    Sore mouth    1 2 2 4  9 (100.0%)   
    Sore throat    0 2 1 2  4 (100.0%)   
    Jaw pain    0 0 1 1  3 (100.0%)   
4. Nausea
b
 
    Nausea    0 10 7 7  21 (91.3%)   
    Vomiting      0 5 2 2  8 (100.0%)                         
5. Fever
b
 
    Fever    1 2 1 1  5 (100.0%)   
    Bruising    1 1 1 1  3 (75.0%)   
6. Respiratory
b
 
    Cough    1 2 1 0  4 (100.0%)   
    Shortness of breath   1 2 5 0  9 (100.0%)   
7. Pain
c
    4 2 11 6  22 (95.7%)   
8. Numbness in fingers and/or toes
c
 2 3 2 5  11 (84.6%)   
9. Bleeding
c
    0 1 0 0  1 (100.0%)   
10. Hair loss
c
    2 1 2 8  14 (93.3%)   
11. Skin changes
c
   0 1 9 14  18 (81.8%)   
12. Constipation
c
   3 5 4 7  19 (95.0%)   
13. Soreness in vein
c
   0 2 2 0  1 (25.0%)   
14. Decreased interest  
     in sexual activity
c
   2 6 3 1  9 (81.8%)  
a
Alleviation occurrence: 1. Seldom done; 2. Done occasionally; 3. Often done; 4. Very often 
done. 
b
TRSC multiple item subscales/clusters. 
c
TRSC single item subscale. 
        
 There were nine symptoms that were alleviated 100% of the time, regardless of the 
method of self-care or the frequency with which it was performed (difficulty swallowing, sore 
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mouth, sore throat, jaw pain, vomiting, fever, cough, shortness of breath, and bleeding).  The 
lowest effectiveness percentage was 25% for soreness in vein.  While this table gives a snapshot 
of the effectiveness of the self-care methods used for symptom alleviation, a constructed case 
using a qualitative approach is described below. 
A Constructed Case Example 
 A woman who might be expected to have a high TRSC score is represented in this 
constructed case.  The woman would have a high school education and be fairly recently out of 
treatment, between 6 months to a year.  She would have had combination therapy that included 
chemotherapy.  The woman with high scores on the TRSC likely would have included additional 
symptoms, beyond the 25 items listed on the TRSC.  Dry mouth and lymphedema were 
commonly added symptoms.  The typical subject with high scores would likely report that the 
alleviation method was used “very often,” and most self-care methods helped relieve the 
symptom.  However, relief measures that were “seldom done” were still effective.   
Summary 
Data analyses included logistic and linear regression analyses, Fisher’s exact test, and 
descriptive and content analyses.  
The primary research question examined the relationship between self-reported symptom 
occurrence and severity as measured by the Therapy-Related Symptom Checklist (TRSC) total 
scores and the presence or absence of the BDNF Val66Met SNP in breast cancer survivors.  
Findings showed that lower TRSC scores were significantly associated with the presence of the 
BDNF Val66Met SNP.  However, this relationship did not persist when controlling for the 
confounders of education and treatment type to the logistic regression model.  
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Secondary research questions 1-3 were investigated using three additional self-report 
measures: Daily Activities Rating Scale (DARS), Health-Related Quality of Life - Linear 
Analogue Self Assessment (HRQOL-LASA), and the Symptom Alleviation: Self-Care Methods 
(SA: SCM) scale.   
With secondary research question 1, a pattern emerged that showed that compared to the 
present BDNF SNP group, the absent BDNF SNP group showed a greater symptom burden.  No 
conclusions could be made due to lack of power. 
With secondary research question 2, logistic regression used five predictors (age, 
education, type of treatment, time since treatment completed, and BDNF variant).  The results 
showed significant odds ratios for education and for treatment type, suggesting that the odds of 
having a low TRSC score are increasingly greater as education increases and are diminished if 
the type of treatment included chemotherapy. 
With secondary research question 3, content analysis showed that the most often used 
self-care symptom alleviation method category was diet/nutrition/lifestyle and the least was 
herbs/vitamins therapy.  The effectiveness of the methods ranged from 25% to 100%, with most 
responses indicating a high percentage of effectiveness regardless of how often the self-care 
alleviation method was done.  The results of the study are discussed in Chapter 5, along with the 
conclusions, implications, and recommendations for further study. 
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Chapter V 
Discussion 
The primary aim of this study was to examine the relationship between self-reported 
symptom occurrence and severity as measured by the Therapy-Related Symptom Checklist 
(TRSC) total scores and the presence or absence of the BDNF Val66Met SNP in breast cancer 
survivors.  Prior to this study, the 25-item TRSC had not been used in conjunction with BDNF 
genotyping.  While the expected result was that higher symptom occurrence and severity scores 
would align with the presence of the variant, the data analysis revealed that those subjects with 
the variant absent had higher scores.  However, the effect size was small. 
 With the Secondary Aims, findings revealed that high symptom occurrence and severity 
on the TRSC was related to problems with activities of daily living (i.e., high scores on the 
DARS), as well as to low quality of life (i.e., low scores on the HRQOL-LASA).  The higher the 
daily activities rating score, the higher the TRSC score and the lower the quality of life. The 
results of the analyses suggested that the odds of having a low TRSC score are increasingly 
greater as the subject’s level of education increased and were diminished if the type of treatment 
included chemotherapy.   
The most common self-care method used was diet/nutrition/lifestyle and the least 
common was herb/vitamins/complementary therapy.  The other category for alleviation methods 
yielded mostly symptom-specific measures.  A constructed case study representative of the most 
symptomatic subjects showed a range of self-care methods used. Results indicated that symptom 
alleviation methods, even those “seldom done”, were perceived as effective.  
 
 
 
 
80 
 
Primary Research Question 
Prior to the initiation of this study, the researcher made certain assumptions based on the 
literature review and experience about how the Val66Met SNP was related to ongoing symptoms 
in breast cancer survivors.  Previous employment in oncology and previous research in the 
course of this degree program led the investigator to believe that the presence of the Val66Met 
SNP would contribute to a higher symptom score; however, the findings revealed the opposite, 
with marginal statistical support.  A possible explanation for these unexpected results was 
explored using a subanalysis of the Fatigue subscale.  However, there was no relationship 
demonstrated between the score from the Fatigue subscale and the presence or absence of the 
variant.   
On further review of the BDNF literature, the frequent use of the word modification, 
previously interpreted in favor of the variant being linked to higher symptom scores, now can be 
understood in its literal sense, meaning simply a change (McEwen 2010, 2011).  McEwen (2010, 
2011) also aptly noted that the ever-changing brain is impacted in ways that make it very 
difficult to predict what predisposes or influences processes.  A literature review of symptom-
reporting measures, including the TRSC, noted that “human biology and behavior are complex 
under normal health states.  These complexities are intensified in the context of health risks or 
adverse health conditions” (Berry, 2011, p. 207).  Feder, Nestler, and Charney (2009) reported 
that the BDNF Val66Met SNP significantly impairs BDNF’s intracellular trafficking, yet other 
studies have shown that the variant enhances resiliency to chronic stress (Gajewski et al., 2011; 
Kennedy, Rodriguez, Land, & Raz, 2009; Krishnan et al., 2007; Noble, Billington, Kotz, & 
Wang, 2011; Qin, Kim, Ratan, Lee, & Cho, 2011; Zivadinov et al., 2007). 
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 According to Feder et al. (2009), the conflicting data underscore the possible 
multifaceted effects of BDNF in the context of a myriad of other factors that impact resilience.  
A study by Krishnan et al. (2007) was able to identify distinct variability among murine 
susceptibility to social defeat.  Further investigation provided some evidence that mice with the 
BDNF polymorphism were more resilient to social defeat and had more interaction time 
subsequent to the social defeat than the mice with the Val/Val genotype.  The investigators 
encouraged future studies with human subjects based on their findings.  A more recent study 
with rats (Taliaz et al., 2011) that seemed to point to the BDNF Val66Met SNP as contributing to 
symptoms led this investigator to discount the conclusions of the older study (Krishnan et al., 
2007).   
There is some evidence in the literature in favor of some type of protective effect for the 
Met gene variant.  In the approximately 700 subjects, studies of healthy individuals (Beste et al., 
2009; Gajewski et al., 2011), patients with multiple sclerosis (Zivadinov et al., 2007), and 
Vietnam veterans (Krueger et al., 2011) found a positive effect of the Met variant.  In 
comparison, there is the preponderance of evidence involving thousands of subjects in studies 
covering various disease states where the Met variant was linked to a negative effect.  The topics 
of study included Post Traumatic Stress Disorder (PTSD; Frielingsdorf et al., 2010), diabetes 
(Gray et al., 2006), Parkinson’s disease (Ahlskog, 2011), anxiety (Hashimoto, 2007), 
schizophrenia (Lu & Martiowich, 2008), bipolar disorder (Grande, Fries, Kunz, & Kapczinski, 
2010), and major depressive disorder (MDD; Castren et al., 2007; Mata, Thompson & Gotlib, 
2010; Terracciano et al., 2011; You et al., 2010).  A meta-analysis of adult attention-deficit 
hyperactivity (ADHD) including almost 1,500 patients and twice that number of controls showed 
no association with BDNF (Sanchez-Mora et al., 2009). 
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Consequently, the evidence is mixed about the relationship between symptoms following 
breast cancer diagnosis and treatment with the presence or absence of the BDNF Val66Met SNP 
in survivors.  More research is needed to examine if the findings of this study could be replicated 
and to determine the implications. 
First Secondary Research Question 
Another surprising result was the finding that time since treatment completed had no 
relationship to the symptom scores.  Typically, not much consideration is given to the longer-
term survivorship phase for older breast cancer survivors (Crane-Okada et al., 2012).  Of high 
importance is the finding that symptoms are reported even after the end of active treatment in 
these breast cancer survivors.  This finding emphasizes the need for continued symptom 
assessment and management post-treatment among breast cancer survivors.  With timely 
education and counseling regarding symptom alleviation and self-care strategies specific to 
symptoms reported on a checklist like the TRSC, suffering may be lessened among breast cancer 
survivors.  In an evidence-based study using the Stetler model, P. D. Williams et al. (2011d) 
reported a significant impact on quality of life by providing education and support as an 
intervention in a sample of cancer patients during active treatment.  P. D. Williams and co-
investigators also tested a pilot intervention comprised of a simple one-hour art-making session 
with oncology patients.  They reported that on two TRSC symptoms, feeling sluggish and 
difficulty concentrating, the intervention group had significantly lower TRSC scores and salivary 
cortisol levels than the control group (Mische-Lawson et al., 2012). 
 A recent study (Kim, Barsevick, Beck, & Dudley, 2012) also identified a 
psychoneurologic symptom cluster in women receiving treatment for breast cancer.  The 
secondary analysis, using cluster analysis of data on 282 women undergoing chemotherapy or 
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radiation therapy, identified a symptom cluster of depressed mood, cognitive disturbance, 
fatigue, insomnia, pain, and decreased functional performance.  Moreover, a qualitative study 
with 18 breast cancer survivors regarding their experience with chemotherapy-related cognitive 
impairment provided a framework for understanding the patient experience (Myers, 2012).  The 
study raised the issue of how this impairment may impact important decisions, including giving 
informed consent.  In the current study, it is noted that “difficulty concentrating” is the symptom 
on the TRSC that would be indicative of cognitive problems. 
The current study also revealed a high frequency and severity of decreased interest in 
sexual activity.  This merits discussion in view of several recent international qualitative studies 
focused on issues related to sexuality and breast cancer.  A study by Chung and Hwang (2012) 
conducted in Korea with seven couples where the wife had breast cancer highlighted problems 
which originated with both partners.  One wife felt sorry for her husband, but she did not have 
any desire because of pain and fear.  Her husband sometimes felt annoyed but could not express 
that to his wife and redirected his sexual energy to playing the saxophone rather than working 
through the relationship with his wife.  This couple reported five years of celibacy.  Another 
study of 18 Iranian men (Nasiri, Taleghani, & Irajpour, 2012) who had wives with breast cancer 
shared their sexual issues.  The men felt they were not informed of what to anticipate, and they 
were not supported in their efforts to cope with their sexual problems.  The participants in that 
study suffered from sexual frustration, but remained faithful to their ill wives by sexual restraint.  
Some did not have sexual desire when they saw their wives’ scars and felt pity instead of 
passion.  One man reported that he and his wife had been able to work through their issues and 
their sexual relationship was much better than before his wife’s treatment for breast cancer.  A 
separate study of Iranian women found that the loss of one or both breasts may lead to altered 
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body image and decreased feelings of sexual attractiveness and function (Tirgari, Iranmanesh, 
Fazel, & Kalantarri, 2012).  Women with gynecological cancer in a Brazilian study reported 
significantly worse sex lives and lower frequency of sexual relations, but felt uncomfortable and 
did not discuss their symptoms with their oncologists (da Silva Lara, de Andrade, Consolo, 
& Romão, 2012). 
Second Secondary Research Question 
High symptom occurrence and severity on the TRSC was related to problems with 
activities of daily living (i.e., high scores on the DARS), as well as to low quality of life (i.e., low 
scores on the HRQOL-LASA).  The analyses suggested that the odds of having a low TRSC 
score are increasingly greater as education increases and are diminished if the type of treatment 
included chemotherapy.  
As mentioned, P. D. Williams et al. (2011b) reported significant intercorrelations among 
the variables of symptom occurrence and severity (as measured by the TRSC), daily activities 
performance (as reported on the DARS), self-care strategies (as reported on the SA: SCM), and 
health-related quality of life (as measured by the HRQOL-LASA) in a sample of U.S. cancer 
survivors of varied diagnoses and ethnicities.  Similar findings also were reported in a sample 
population in Puerto Rico (Gonzalez et al., 2011). 
 Many studies also have reported the high impact of chemotherapy on symptoms, 
including a recent Norwegian study that found that chemotherapy doubled the number of 
symptoms reported by the subjects (Hofso, Miaskowski, Bjordal, Cooper, & Rustoen, 2012).  
The impact of symptoms goes beyond the obvious discomfort, as symptoms may cause 
uncertainties about prognosis, resulting in additional anxiety and distress that decrease quality of 
life (Cahill, LoBiondo-Wood, Bergstrom, & Armstrong, 2012).  Difficulty sleeping is a common 
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and disturbing symptom (Erickson & Berger, 2011) that affects various physiological pathways 
(Wu et al., 2012). 
 Parallels with Alzheimer’s Disease (AD) and impact of education on symptoms.  One 
of the most unexpected findings in the current study was the impact of education.  A great deal 
of literature exists on the effect of level of education attained by subjects on the symptoms of 
AD. There are a number of parallels between the current study and what has been previously 
discussed in the AD literature.  A concept called cognitive reserve may have some applicability 
as to why educated subjects in the current study were inclined to less frequently identify 
symptoms, and tended to perceive the symptoms that they did identify as less severe.  A number 
of studies have explored this model (Koepsell et al., 2008; Paradise, Cooper, & Livingston, 
2009; Roe, Xiong, Miller, & Morris, 2007; Roselli et al., 2009). 
The importance of understanding the underlying physiology of AD would be of 
considerable value to society (Brayne et al., 2010).  Five primary physiological areas, or 
biomarkers, have been studied in relationship to symptoms in AD and the relationship to 
education: cortical thickness (Seo et al., 2011), regional cerebral blood flow (Chiu, Lee, Hsiao, & 
Pai, 2004), dendritic plaques or tangles (Bennett et al., 2003), amyloid load (Roe et al., 2008; 
Vemuri et al., 2011), and genetic influence.  Of particular interest for this discussion is the 
genetic influence. 
The genetic variant most often studied in relationship to AD symptoms is apolipoprotein.  
To estimate the effect of education on the risk of AD symptoms, a Norwegian study enrolled 373 
patients diagnosed with AD and 559 healthy control individuals (without first degree relatives 
with known dementia) in a case-control study that was conducted over three years between 2003 
and 2006.  All individuals were genotyped for apolipoprotein (APOE) alleles.  The odds ratio for 
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developing AD was calculated using binary logistic regression.  The number of apolipoprotein 
epsilon 4 (APOE e4) alleles and educational level were entered as covariates.  It was found that 
carriers of one APOE e4 allele had an odds ratio of 4.2, and carriers of two APOE e4 alleles had 
an odds ratio of 12.4 for developing AD.  Thus, these studies indicated that education has a 
protective effect on the risk of developing clinical AD in a dose-dependent manner (Baek et al., 
2011; Sando et al., 2008; Shadlen et al., 2005).  Applicability to this study included the fact that 
a genetic influence may be potentiated by a variable such as education. 
A 10-year longitudinal French study began in 1988 and involved nearly 3,000 subjects.  
A subsample of 600 participants was examined for the APOE e4 allele that has been shown to be 
a risk factor for dementia.  The decrease in the Mini-Mental Status Examination score (MMSE) 
that was initially associated with the presence of the APOE e4 allele disappeared when adjusted 
for education (Winnock et al., 2002). 
The AD literature also explores the social or coping support aspect of education that has 
been the focus of a number of large studies.  A 3-year study conducted in a biracial community 
sample of older adults (N = 3,097) found that education and literacy may be protective factors 
against cognitive dysfunction and attenuated the effect of race (Sachs-Ericcson & Blazer, 2005).  
Individuals with higher education attainment may maintain better health and hygiene and be 
exposed to richer environments, in turn delaying the onset of symptoms or being better able to 
cope with symptoms (DenBesten, 2009).  A cross sectional study of aging individuals (ages 71 - 
87 with 74% female) free from dementia (N = 951) suggested that education was one of the 
most-robust proxy measures of cognitive reserve (Jefferson et al., 2011).  In a community south 
of Chicago, over 10,000 older community members were enrolled and baseline data were 
collected.  The data included four tests of cognitive function, U.S. census questions about race, 
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occupation, and income levels, as well as presence of five health conditions (myocardial 
infarction, hypertension, stroke, diabetes, and cancer).  The mean age of the participants was 72, 
61% were female, and 67% were black.  The first follow-up in three years had slightly fewer 
than 7,000 respondents although the mean time for observation was 6.5 years with some 
participants providing data up to 14 years after the initial home interview.  The mean educational 
level was 12 years and was still found to be a robust protector against cognitive decline with 
aging (Wilson et al., 2009).  The research in the AD literature is extensive, and the impact of the 
physiological and genetic influences in AD have parallels to the current study, particularly 
linking the influence of education to symptoms as addressed by the secondary research question. 
 Older age of sample.  Patterson, Millar, Desille, and McDonald (2012) described the 
impact of cancer on emerging adults.  Although the sample was largely older, 19 subjects (9.7% 
of the sample) for this dissertation study were 18-26 years old.  The higher scores on the TRSC 
in younger subjects might be related to the tasks of the emerging adults.  Patterson et al. (2012) 
discussed the issue that having cancer in addition to the developmental stressors of emerging 
adults could help to explain why younger age was related to higher TRSC scores.  In this young 
adult age group, stressors would include family tasks such as raising young children.  Age may 
be an important contextual factor when making decisions and managing cancer therapies, as 
revealed in a literature review by Tarriman (2011).   
 Data reliability.  Due to the subjective nature of self-reported data, there could be 
questions about the reliability of the data.  Also, despite specific instructions to report currently 
experienced symptoms, several subjects were confused about whether to report symptoms 
currently being experienced or symptoms as they were experienced at the time of treatment. 
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 Subjectivity impact on self-report.  Meeting with the Phase 2 participants provided some 
opportunity to verify the accuracy of Phase 1 data.  One Phase 2 participant had a full head of 
hair, but she rated her hair loss as a 4 (very severe) as her hair was not as thick, still came out, 
and she had lost her eyebrows permanently.  In contrast, a subject whose TRSC score was zero 
had difficulty producing the saliva sample due to dry mouth.  She verbally reported that dry 
mouth contributed to taste changes and loss of appetite, and the generalized dryness caused other 
skin issues.  She had not rated any items on the TRSC as she did not consider them "problems" 
but just changes.  The symptom occurrence and severity rating for this study was impacted by 
the perceptions of the individuals.   
Time frame confusion.  There was some confusion about the time period that was to be 
evaluated for a few participants, current versus during treatment.  Although specific instructions 
were given to report current symptoms in the online survey, in a one-week follow-up email, and 
in response to any phone or email questions by participants, it was discovered in the Phase 2 
personal interviews that several respondents were confused about the time period.  There is no 
way of detecting if confusion about the time period was an issue for other on-line respondents.  
When meeting with the Phase 2 subjects, all except two high-scoring Phase 2 participants were 
clear that their ratings were to be based on current symptom experiences rather than symptoms 
experienced during treatment.  These two scores would have been lower if they had been rating 
current symptoms.  Conversely, a number of respondents wanted to raise their scores based on 
current exacerbations of symptoms.  No adjustments were made to the scores that were originally 
entered by the subjects.  
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Third Secondary Research Question 
The third secondary research question addressed the use and effectiveness of self-care 
methods.  A review by Shulman-Green et al. (2012) of 101 studies in a meta-analysis revealed 
that self-management plans vary in importance to patients over time.  Communication about the 
self-management plan is of critical importance to both patient and caregivers (Shulman-Green et 
al., 2012).  The importance of continued menopausal symptom assessment and management 
supports the importance of continuing nursing care for breast cancer survivors who are already 
using hot flash treatment, and suggests that nursing interventions aimed at improving perceived 
control over hot flashes may be more helpful for survivors than for midlife women (Carpenter, 
Wu, Burns, & Yu, 2012).  Hot flashes were one of the symptoms that was added when the 
subjects in this study were given the opportunity to list additional symptoms on the TRSC.  
Although women who have not experienced cancer may have hot flashes, this symptom may be 
more troublesome for the breast cancer survivors.  
The literature also revealed that several studies focused on self-care have been conducted 
using the TRSC in the United States, as well as in Asia, Europe, and Puerto Rico.  Findings 
similar to the present study have been reported.  A descriptive study (P. D. Williams et al., 
2006a) was conducted with 37 adults living in the Midwestern United States who were receiving 
chemotherapy for leukemia, lymphoma, or breast cancer or radiation for head and neck cancer.  
Study participants reported their symptoms on the TRSC and also described the symptom 
alleviation methods they used to help control their symptoms.  The reported results showed that 
(a) 10 symptoms were reported as mild to moderate in severity, and 40% or more of the patients 
reported at least 17 symptoms on the TRSC; (b) care providers prioritized interventions based on 
the TRSC patient-reported symptom occurrence and severity scores; and (c) the self-care 
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strategies, grouped according to complementary medicine categories as a framework, showed 
that the two categories most used were diet/nutrition/lifestyle change and mind/body control.  
Responses also indicated the use of biological products, such as vitamins, and the use of herbal 
treatments and ethno-medicine, such as lime juice and garlic, green mint tea, and others, to 
alleviate symptoms.   
The above study was replicated in cancer centers in Hong Kong and in mainland China 
(Xi’an) using 222 adult oncology patients.  The findings were similar to the findings of the study 
done in the Midwestern United States.  Self-care strategies most often used fell in the same two 
categories (diet/nutrition/lifestyle change and mind/body control) and were reported as helpful 
by the patients.  Tai-chi was mentioned by some as part of mind/body control self-care measures 
utilized by the Chinese patients; biological treatments were also utilized (P. D. Williams et al., 
2010b).   
Another replication of the study was conducted with 100 oncology patients at the national 
medical center in the Philippines, located in the city of Manila.  Findings similar to the studies 
conducted in China and the United States were reported.  The self-care methods most often used 
by patients in the Philippines fell into two categories.  The first types of self-care methods 
utilized were diet/nutrition/lifestyle changes, such as modifying food and eating habits, eating 
vegetables and fruits such as papaya, using nutritional supplements, taking naps, and getting 
adequate rest and sleep.  These self-care methods were all mentioned as useful to manage the 
Eating and Fatigue subscale symptoms.  The second types of self-care methods reported by 
patients were in the mind/body control category, such as prayer, praying the rosary, and listening 
to music; these self-care methods were used to relieve the symptoms in the Fatigue 
subscale/cluster, as well as other symptoms (P. D. Williams et al., 2010a).  The key role of 
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family support during treatment also was described by the patients, similar to findings on 
Filipino-Americans reported by Harle et al. (2007).  In TRSC replications with Puerto Rican 
patients and Mexican-American patients undergoing treatment for cancer, two other studies have 
reported similar quantitative findings.  Moreover, qualitative findings have shown that patients 
focus on religious practices and utilize the support of family as part of self-care strategies 
(Gonzalez et al., 2010; Lantican et al., 2011), similar to practices employed by the patients in the 
Philippine study.   
Another replication study was conducted in Thailand using the TRSC and similar 
methods, with a convenience sample of 202 patients receiving treatment for cancer at the 
National Cancer Institute, as well as at a cancer center of a provincial city in Thailand 
(Piamjariyakul et al., 2010).  The results closely mirrored those previously reported in the studies 
conducted in the Midwestern United States, mainland China, and the Philippines.  One of the 
unique self-care findings reported in Thailand was the use of the herbal treatment “purple 
flower” for hair loss.  The use of music and religious icons were also common, including the use 
of tapes related to Buddhist prayers.  The TRSC, DARS, HRQOL, and SA: SCM measures have 
been used extensively in studies by P. D. Williams and colleagues, and further analysis of data 
from these studies may provide additional relevance to the data from this study.   
The literature clearly indicates self-care methods are widely used.  An understanding of 
what methods have been successfully utilized could be used to optimize care.  Further study may 
provide more robust support for specific recommendations for patient teaching in preparation for 
the expected long trajectory of symptom management. 
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Theoretical Relevance  
 The physiological model (Figure 2 in Chapter 1) was used to design this study.  Data 
collected did not provide clear evidence to support the model.  Additional literature reviewed did 
provide some context for the interpretation of the finding that varied from the original 
expectation.  The original expectation was that the homozygous high-activity Val allele would be 
linked to less symptoms as there would be greater neuroplasticity and repair mechanisms 
available (Kennedy et al., 2009).  It was believed that the less active Met gene variant would 
exacerbate symptoms rather than provide the protective effect that was demonstrated.  A better 
understanding of how these genetic influences, such as the BDNF Val66Met SNP, affect various 
physiological processes is needed (Noble et al., 2011). 
 Expanding on Table 1 (found in Chapter 1), Table 14 below shows a related conceptual 
framework, the study results, and some recommendations for further research.  
Table 14 
Concepts and Empirical Indicators for Future Research 
Concepts Daily activities Quality of Life Symptoms Sample 
characteristics 
Emperical 
indicators 
(operationalization) 
Daily Activities 
Rating Scales 
(DARS) 
5-item scale 
Health Related 
Quality of Life 
(HRQOL)-Linear 
Analog Self 
Assessment (LASA) 
6-item scale 
Therapy Related 
Symptom Checklist 
(TRSC) 
25-item scale 
Five self-reported: 
age, ethnicity, 
education, 
treatment type, and 
time since treatment 
completion 
Level of 
measurement 
Ordinal Ordinal Ordinal Nominal/ordinal 
Analytic strategy Linear regression Linear regression Linear regression Linear regression 
Results DARS related to 
HRQOL-LASA 
HRQOL-LASA 
related to DARS 
TRSC related to 
DARS 
TRSC related to 
HRQOL-LASA 
No relationships 
with time since 
completion of 
treatment or 
ethnicity 
 
Recommendations 
for further studies 
More subjects who 
are not Caucasian, 
with lower 
education, rural and 
urban residents   
More subjects who 
are not Caucasian, 
with lower 
education, rural and 
urban residents 
More subjects who 
are not Caucasian, 
with lower 
education, rural and 
urban residents 
More subjects who 
are not Caucasian, 
with lower 
education, rural and 
urban residents 
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Clinical Implications 
 The findings of this study support the need for sustained symptom assessment and 
management post-treatment among breast cancer survivors.  Continuing self-care is the key to 
symptom alleviation in the years when survivors will still be experiencing symptoms but have 
limited contact with providers.  Nurses are pivotal to monitoring and intervening in the 
management of symptoms and maximizing of quality of life (Thomas, Crisp, & Campbell, 
2012).  According to the evidence hierarchy defined by Polit and Beck (2008), this current study 
provides Level IV evidence for practice; it is a single correlational (multiple regression) 
biobehavioral, physiologic study, with a mixed method (qualitative) component.  The evidence 
for practice gained from this study includes the fact that breast cancer survivors have significant 
ongoing symptoms long after treatment is completed.  These symptoms require continuing 
assessment and guided self-care to alleviate symptoms among these cancer survivors.  Using a 
multiple symptoms assessment tool, such as the TRSC, to guide symptom management 
optimizes the care provided to patients.   
P. D. Williams et al. (2011d), in an evidence-based study using the Stetler model, 
reported significant outcomes of education and support on quality of life in a sample of cancer 
patients during active treatment.  Resources, such as the Oncology Nursing Society (ONS, 2010) 
and Yarbro, Frogge, and Goodman (2004), helped guide the interventions used in the Williams 
study.  Moreover, Mische-Lawson et al. (2012) also reported that on two TRSC symptoms 
(feeling sluggish and difficulty concentrating), the “art-making” intervention group had 
significantly lower TRSC scores and salivary cortisol levels than the control group.  These 
interventions could be extended to include long-term breast cancer survivors; combining these 
evidences can positively impact patient experience.  Techniques such as Pilates that can be 
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advocated by nurses may be helpful for breast cancer patients to reduce symptoms and increase 
quality of life, and these interventions can be used on an ongoing basis without the risk of or 
need for continued medical care (Stan et al., 2012).  Also, a literature review of 22 articles 
highlighting the benefits of social support and physical activity in cancer survivors (Barber, 
2012) found that less than 20% of adult cancer survivors participate in physical activity and, as a 
result, are at greater risk for problems due to the inactivity.  Lack of social support was 
implicated as having a significant negative relationship with physical activity engagement in 
50% of the studies reviewed.  Nursing interventions centered on social support and physical 
activities have the potential to make an impact as self-care to improve symptoms, such as 
fatigue, depression, and other symptoms, and could contribute to improved quality of life.  
Another recent study showed that use of the TRSC improves symptom documentation and 
management, as well as HRQOL (P. D. Williams et al., 2012a). 
  A study of 318 patients indicated that motivational interviewing by nurses can assist with 
symptom management (Thomas, Elliot, et al., 2012).  Chemotherapy, not surprisingly, seems to 
contribute the most to the symptom burden, and this evidence has been previously demonstrated 
in a number of studies by P. D. Williams et al. (2001; 2010a, b); Piamjariyakul et al. (2010); and 
Vath & Williams (2012).  Nurses may have a large impact on self-care by supporting 
individuals’ care for symptoms such as depression (Qian & Yuan, 2012).  The clinical 
implication of targeted nursing interventions, in conjunction with a simple assessment to gather 
age and education information, may be as important as a specialized genetic test.  
 Decreased interest in sexual activity, noted by 82.1% of respondents, had the third 
highest symptom occurrence after difficulty concentrating (87.2%) and feeling sluggish (84.6%) 
in this study.  As previously discussed, decreased interest in sexual activity may cause a great 
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deal of suffering for survivors; the mean severity was 1.85, second only to hair loss (2.10).  The 
standard of practice for nurses is to address sexuality issues.  One evidence-based tool to support 
nursing practice is the BETTER Model (Mick, Hughes, & Chen, 2004) that could be used to 
assist oncology nurses to conduct sexuality assessments more effectively.  The evidence 
provided by the present study about the occurrence and severity of this problem as an ongoing 
symptom for breast cancer survivors is a challenge to professional nurses to use the available 
tools to support their practice. 
 The long trajectory of symptoms associated with breast cancer has important implications 
for undergraduate nursing education.  Nurses entering practice need to be better able to assist 
women in managing their self-care, even years after the survivors complete their treatment 
regimens.  Additionally, this type of information needs to be conveyed in graduate nursing 
programs, specifically to those nursing students specializing in oncology.  Research in this 
critical area of inquiry should move forward, and graduate nursing research will be one of the 
most powerful mechanisms to drive the research.  Further research could pave the way for use of 
the BDNF Val66Met SNP genetic indicator as a screening tool.  Identifying at-risk individuals so 
that protective nursing measures could be applied more aggressively to the personalized 
survivorship care plan could be important if the SNP that seems to provide a protective effect is 
absent. 
Study Strengths and Limitations 
One strength of the study was that it did provide preliminary information about a 
previously unstudied relationship between the BDNF Val66Met SNP and cancer symptoms.  
However, the sample size was very small, and although definitive evidence for a particular 
 
 
96 
 
relationship has not been established through this study, this research provides information for a 
future, larger, and better-controlled study.  
The scientific approach aids in being better able to explain the human condition, yet all 
nursing research is inherently limited.  In applying the scientific method, limitations for this 
study included the fact that the small convenience sample consisted of volunteers with one type 
of cancer.  These volunteer participants were all located in a limited geographical region.  These 
sampling deficiencies were taken into account when data were analyzed and results were 
reported in this preliminary study.  One inherent disadvantage of the electronic survey is that 
there could be multiple and mischievous responses (Duffy, 2002).  The design attempted to 
enrich the sample for Phase 2 of the study, which addresses the primary research question. 
Additionally, there may have been many important confounding variables that cannot be 
explained with the data collected.  One example is that type of treatment, stage of disease, and 
many other factors have been demonstrated to impact symptoms.  All medical information was 
self-reported; no medical information verification has been included as part of the study.  The 
complexities of the issues involved could only be properly addressed by a carefully controlled 
study.  To the extent possible in this study, statistical control of selected variables was done with 
logistic and multiple regression analyses.  
Finally, measurement problems were an issue with this study.  The self-report 
instruments used in this study have had limited usage electronically (P. D. Williams et al., 
2011b).  However, others have electronically administered self-report instruments in their 
research (Basch et al., 2007).  Factors that may have impacted data collection include problems 
with access to the electronic survey and length of the survey.  The length of the survey might 
have contributed to partial rather than complete responses, as evidenced in the pattern of missing 
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items, which seemed to be related to page breaks in the survey.  Difficulties with scheduling or 
traveling to the sites for Phase 2 were a definite limitation that eliminated at least 10 potential 
subjects.  In order to counter this problem, the researcher offered five routine locations and 
utilized alternate locations, such as libraries and restaurants, and made home visits as needed.  
Even though the invitation to participate in Phase 2 included information that a saliva sample 
would be collected, when phone contact was made to schedule appointments, three potential 
subjects declined, specifically citing their unwillingness to give a saliva sample.  The integrity of 
the saliva samples also may have been problematic.  Although guidelines about collecting a good 
saliva sample were reviewed with the potential subjects during the scheduling call, there was no 
control over their activities previous to the face-to-face meeting.  The researcher did need to 
remind at least five participants that it would not be appropriate to drink prior to the saliva 
collection during the Phase 2 visit.  
In this study a homogeneous convenience sample was a limitation.  The type of 
demographic data and the manner in which the data were gathered were also problematic.  Use 
of continuous variables such as age, rather than age categories, would have made some aspects 
of data analysis more powerful.  The methodological problems that contributed to missing data 
were a limitation.  There may also have been some confusion in some participants regarding the 
time period considered in the rating of symptoms.  The online data collection method did not 
allow subjects to ask any questions for clarification although the opportunity to email or call did 
provide some assistance for subjects.  In retrospect, the researcher should have used the 
opportunity to gather more specific demographic information during the Phase 2 face-to-face 
meetings with participants.  
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Recommendations for Future Research 
 Future research needs to be conducted to further explore links between breast cancer 
symptoms and possible biological markers such as the BDNF Val66Met SNP.  Exploring this 
relationship with other cancer diagnoses, including colorectal cancer, lung cancer, and prostate 
cancer, is suggested.  As in many studies, a larger sample would enable a more robust 
examination of the relationships among variables.  Further research with a more diverse sample, 
with particular regard to ethnicity, would be recommended to gain a better understanding of this 
phenomenon.  Level of education as related to residential location (rural, urban) would provide 
important information for health care delivery.  Table 14 shows specific recommendations for 
further research as related to the study variables.  A better controlled study would be an 
important scientific improvement.  In future studies, the collection of continuous data whenever 
possible is recommended.  The use of online data collection is a special problem with the format 
and length of questions asked, in addition to HIPAA considerations.  Methodology that would 
include medical records review would allow verification of participants’ self-reported health 
information.  Continued use of methods to ensure the reliability of the information is 
emphasized.  In this study, for example, the researcher directly administered the SA: SCM 
instrument to Phase 2 participants; this increased the reliability of data gathered. 
Conclusions 
The study conclusions will be addressed by listing conclusions stemming from each 
research question.  Relative to the primary research question, findings showed that lower TRSC 
scores were significantly associated with the presence of the BDNF Val66Met SNP.  However, 
this relationship did not persist with the addition of education and treatment type to the logistic 
regression model.  More research is needed to explore the effect of the BDNF Val66Met SNP, 
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particularly as it relates to the possibility of using the genetic marker as an indicator of 
vulnerability. 
The conclusions corresponding to the secondary research questions include foremost the 
fact that the occurrence and severity of symptoms among breast cancer survivors are ongoing 
issues, beyond the end of formal oncology treatments.  Thus, most of the symptom burden falls 
on the individual survivor outside of the time when they had frequently interacted with medical 
professionals.  This makes the issue of self-care among survivors imperative for successful 
symptom alleviation.  The clinical implications for the most frequently occurring symptom, 
difficulty concentrating, might include primarily teaching survivors that this is likely to be a long 
term issue.  Notably, “difficulty concentrating” is a TRSC symptom indicator for cognitive 
problems among patients.  Thus, the term “cognitive problems,” commonly used when PubMed, 
Medline, and CINAHL are used for literature searches, would miss many studies unless the 
indicator symptom “difficulty concentrating” is added also as a search term.  A researcher had 
recently discovered this issue.  
Participants in this study reported as useful various self-care symptom alleviation 
strategies (such as consciously focusing, taking notes, and using lists and reminders).  Difficulty 
concentrating is one of four symptoms in the TRSC Fatigue subscale, or symptom cluster. 
Therefore, additional survivorship planning should be done to also assess the incidence of 
depression, feeling sluggish, and difficulty sleeping.  Possible interventions for one symptom 
may influence the other symptoms in the cluster.  For example, suggestions for interventions on 
how to improve sleep may prove more valuable to improving difficulty concentrating than 
making a list, or both strategies may actually be helpful.  
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The importance of good nursing assessment is highlighted by this study.  In 1994, the 
study by Youngblood et al. had reported the significant under-reporting of symptoms of cancer 
patients – that was almost 20 years ago.  A recent study with the Mayo Health System by P. D. 
Williams et al. (2012a) reported that, compared with nonuse of a checklist, use of the TRSC 
checklist in health care delivery at a cancer center resulted in more symptoms managed and in 
patients’ reports of (a) higher quality of life and (b) higher functional status.  Replication of this 
study is much needed.   
Another implication of the study is that less-educated individuals might be more 
vulnerable to suffering from symptoms.  Less-educated patients in rural, remote areas may be 
part of this vulnerable group.  Vath and Williams (2012) recently reported that, at a rural 
oncology setting in the Midwestern United States, type of treatment was associated with 
symptoms manifested.  That is, similar to the present study findings, more symptoms were 
observed in patients on chemotherapy, as compared to those on radiation therapy.  However, 
Williams et al. (2001) also had reported this finding at a Midwestern urban medical center.  The 
finding that ethnicity has no impact on symptoms in this study is mainly because all but one of 
the participants were Caucasian; thus, further research with a more diverse sample is needed.  
Moreover, in this study, the fact that many breast cancer survivors listed decreased interest in 
sexual activity as a problem, and yet most of them did nothing to relieve the symptom, should 
cause nurses to reflect about assessment and interventions that are survivor-centered.  Problems 
with sexuality demand a self-care based approach.  Perhaps failure to promote self-care is more 
startlingly evident with this symptom, as well as with the TRSC symptom of depression.  
Therefore, the question is asked again: During clinical care, do nurses fail to properly assess a 
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full range of symptoms in an evidence-based manner with the use of a checklist such as the 
TRSC?  Further research is important to answer this and other questions. 
 Relative to the third secondary research question, the most frequent self-care symptom 
alleviation category was diet/nutrition/lifestyle and the least was herbs/vitamins/complementary 
therapy.  Symptom alleviation methods used in the U. S. (Lantican et al., 2011; P. D. Williams et 
al., 2006a, 2006b) and in other cultures (Gonzalez et al., 2011; Piamjariyakul et al., 2012; P. D. 
Williams et al., 2010a, 2010b) described earlier in Chapter 2 show many similarities in the use of 
self-care and complementary care methods to those self-care methods used in the current study.  
In this study, the effectiveness of the methods ranged from 25% to 100%, with most being highly 
effective.  The implication is that self-care is helpful, and patients should be encouraged to try 
some of the methods suggested by the cancer survivors in this study.  
Summary 
This study provided beginning evidence (Polit & Beck, 2008) that there is an association 
with the BDNF Val66Met SNP presence and lower TRSC scores.  The SNP, as well as 
education, may have a protective effect against symptom occurrence and severity.  Self-care 
methods used are generally effective.  Implications of the study are important for nurses who 
practice clinically in oncology as well as educators.  Assessment, intervention, and self-care 
promotion are essential; this study found that symptom burden impacted cancer survivors even 
beyond the cessation of their treatments for cancer.  This study provides the basis for further 
research.  
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Appendix B 
Recruitment Flyer 
 
If you are a female breast cancer survivor, 18 years of age or older, who has completed treatment 
at least 6 months ago, you are eligible to participate in a study that the coalition is promoting.  If 
you would like to participate in the electronic survey, please call the coalition office or visit the 
coalition web site. 
 
 
Kelly A. Kershaw 
 
Administrative Assistant 
Delaware Breast Cancer Coalition 
111 W. 11th Street, Suite 3 
Wilmington, DE 19801 
(302) 778-1102 x 10 
www.debreastcancer.org 
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Appendix C 
 
Phase 1 Electronic Survey 
 
Hello, my name is Sylvia Heinze. I would like to invite you to participate in my 
doctoral research survey. Your responses are important to the improved care of future 
breast cancer survivors. 
Let me tell you a little bit more about me and my research. I am a practicing oncology 
nurse, and a doctoral student at the University of Kansas. This study is part of my PhD 
research on nursing care for breast cancer survivors. The survey is designed for 
women age 18 years and older who have completed their treatment for breast cancer 
at least 6 months ago. If this describes you, then I would like to invite you to 
participate in this survey. Please answer all of the questions by choosing the answer 
that best describes your current experiences as a breast cancer survivor. There are no 
right or wrong answers. It should take less than half an hour to complete the survey. 
Thank you for choosing to participate. If you have any questions about the study, 
please feel free to contact me: 
 
Sylvia Heinze 
302-519-3068 
sheinze@kumc.edu 
 
Symptoms and Breast Cancer Survivors 
 
Created: December 16 2011, 12:46 PM 
Last Modified: January 05 2012, 5:29 PM 
Design Theme: Tablet 
Language: English 
Button Options: Custom: Start Survey: "Start Survey!"  Submit: "Submit" 
Disable Browser “Back” Button: False 
 
 
Symptoms and Breast Cancer Survivors 
 
Page 1 - Question 1 - Choice - One Answer (Bullets) [Mandatory] 
I am a female breast cancer survivor who is 18 years of age or older and have completed treatment 6 
months ago or longer 
 
 yes [Skip to 3] 
 no [Screen Out] 
 
Page 2 - Heading  
The first section of this survey lists 25 problems that are commonly experienced by those who have 
survived cancer treatments. Please select the option that best describes the severity of your personal 
experience with each problem listed. 
Description 
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Page 2 - Question 2 - Choice - One Answer (Bullets) [Mandatory] 
Weight loss 
 
 0 = NONE-NO PROBLEM WITH THIS SYMPTOM 
 1 = MILD 
 2 = MODERATE 
 3 = SEVERE 
 4 = VERY SEVERE 
 
Page 2 - Question 3 - Choice - One Answer (Bullets) [Mandatory] 
Taste change 
 
 0 = NONE-NO PROBLEM WITH THIS SYMPTOM 
 1 = MILD 
 2 = MODERATE 
 3 = SEVERE 
 4 = VERY SEVERE 
 
Page 2 - Question 4 - Choice - One Answer (Bullets) [Mandatory] 
Loss of appetite 
 
 0 = NONE-NO PROBLEM WITH THIS SYMPTOM 
 1 = MILD 
 2 = MODERATE 
 3 = SEVERE 
 4 = VERY SEVERE 
 
Page 2 - Question 5 - Choice - One Answer (Bullets) [Mandatory] 
Nausea 
 
 0 = NONE-NO PROBLEM WITH THIS SYMPTOM 
 1 = MILD 
 2 = MODERATE 
 3 = SEVERE 
 4 = VERY SEVERE 
 
Page 2 - Question 6 - Choice - One Answer (Bullets) [Mandatory] 
Vomiting 
 
 0 = NONE-NO PROBLEM WITH THIS SYMPTOM 
 1 = MILD 
 2 = MODERATE 
 3 = SEVERE 
 4 = VERY SEVERE 
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Page 3 - Question 7 - Choice - One Answer (Bullets) [Mandatory] 
Sore mouth 
 
 0 = NONE-NO PROBLEM WITH THIS SYMPTOM 
 1 = MILD 
 2 = MODERATE 
 3 = SEVERE 
 4 = VERY SEVERE 
 
Page 3 - Question 8 - Choice - One Answer (Bullets) [Mandatory] 
Cough 
 
 0 = NONE-NO PROBLEM WITH THIS SYMPTOM 
 1 = MILD 
 2 = MODERATE 
 3 = SEVERE 
 4 = VERY SEVERE 
 
Page 3 - Question 9 - Choice - One Answer (Bullets) [Mandatory] 
Sore throat 
 
 0 = NONE-NO PROBLEM WITH THIS SYMPTOM 
 1 = MILD 
 2 = MODERATE 
 3 = SEVERE 
 4 = VERY SEVERE 
 
Page 3 - Question 10 - Choice - One Answer (Bullets) [Mandatory] 
Difficulty swallowing 
 
 0 = NONE-NO PROBLEM WITH THIS SYMPTOM 
 1 = MILD 
 2 = MODERATE 
 3 = SEVERE 
 4 = VERY SEVERE 
 
Page 3 - Question 11 - Choice - One Answer (Bullets) [Mandatory] 
Jaw pain 
 
 0 = NONE-NO PROBLEM WITH THIS SYMPTOM 
 1 = MILD 
 2 = MODERATE 
 3 = SEVERE 
 4 = VERY SEVERE 
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Page 4 - Question 12 - Choice - One Answer (Bullets) [Mandatory] 
Shortness of breath 
 
 0 = NONE-NO PROBLEM WITH THIS SYMPTOM 
 1 = MILD 
 2 = MODERATE 
 3 = SEVERE 
 4 = VERY SEVERE 
 
Page 4 - Question 13 - Choice - One Answer (Bullets) [Mandatory] 
Numbness in fingers and/or toes 
 
 0 = NONE-NO PROBLEM WITH THIS SYMPTOM 
 1 = MILD 
 2 = MODERATE 
 3 = SEVERE 
 4 = VERY SEVERE 
 
Page 4 - Question 14 - Choice - One Answer (Bullets) [Mandatory] 
Feeling sluggish 
 
 0 = NONE-NO PROBLEM WITH THIS SYMPTOM 
 1 = MILD 
 2 = MODERATE 
 3 = SEVERE 
 4 = VERY SEVERE 
 
Page 4 - Question 15 - Choice - One Answer (Bullets) [Mandatory] 
Depression 
 
 0 = NONE-NO PROBLEM WITH THIS SYMPTOM 
 1 = MILD 
 2 = MODERATE 
 3 = SEVERE 
 4 = VERY SEVERE 
 
Page 4 - Question 16 - Choice - One Answer (Bullets) [Mandatory] 
Difficulty concentrating 
 
 0 = NONE-NO PROBLEM WITH THIS SYMPTOM 
 1 = MILD 
 2 = MODERATE 
 3 = SEVERE 
 4 = VERY SEVERE 
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Page 5 - Question 17 - Choice - One Answer (Bullets) [Mandatory] 
Fever 
 
 0 = NONE-NO PROBLEM WITH THIS SYMPTOM 
 1 = MILD 
 2 = MODERATE 
 3 = SEVERE 
 4 = VERY SEVERE 
 
Page 5 - Question 18 - Choice - One Answer (Bullets) [Mandatory] 
Bruising 
 
 0 = NONE-NO PROBLEM WITH THIS SYMPTOM 
 1 = MILD 
 2 = MODERATE 
 3 = SEVERE 
 4 = VERY SEVERE 
 
Page 5 - Question 19 - Choice - One Answer (Bullets) [Mandatory] 
Bleeding 
 
 0 = NONE-NO PROBLEM WITH THIS SYMPTOM 
 1 = MILD 
 2 = MODERATE 
 3 = SEVERE 
 4 = VERY SEVERE 
 
Page 5 - Question 20 - Choice - One Answer (Bullets) [Mandatory] 
Hair loss 
 
 0 = NONE-NO PROBLEM WITH THIS SYMPTOM 
 1 = MILD 
 2 = MODERATE 
 3 = SEVERE 
 4 = VERY SEVERE 
 
Page 5 - Question 21 - Choice - One Answer (Bullets) [Mandatory] 
Skin changes 
 
 0 = NONE-NO PROBLEM WITH THIS SYMPTOM 
 1 = MILD 
 2 = MODERATE 
 3 = SEVERE 
 4 = VERY SEVERE 
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Page 6 - Question 22 - Choice - One Answer (Bullets) [Mandatory] 
Soreness in veins where chemotherapy was given 
 
 0 = NONE-NO PROBLEM WITH THIS SYMPTOM 
 1 = MILD 
 2 = MODERATE 
 3 = SEVERE 
 4 = VERY SEVERE 
 
Page 6 - Question 23 - Choice - One Answer (Bullets) [Mandatory] 
Difficulty sleeping 
 
 0 = NONE-NO PROBLEM WITH THIS SYMPTOM 
 1 = MILD 
 2 = MODERATE 
 3 = SEVERE 
 4 = VERY SEVERE 
 
Page 6 - Question 24 - Choice - One Answer (Bullets) [Mandatory] 
Pain 
 
 0 = NONE-NO PROBLEM WITH THIS SYMPTOM 
 1 = MILD 
 2 = MODERATE 
 3 = SEVERE 
 4 = VERY SEVERE 
 
Page 6 - Question 25 - Choice - One Answer (Bullets) [Mandatory] 
Decreased interest in sexual activity 
 
 0 = NONE-NO PROBLEM WITH THIS SYMPTOM 
 1 = MILD 
 2 = MODERATE 
 3 = SEVERE 
 4 = VERY SEVERE 
 
Page 6 - Question 26 - Choice - One Answer (Bullets) [Mandatory] 
Constipation 
 
 0 = NONE-NO PROBLEM WITH THIS SYMPTOM 
 1 = MILD 
 2 = MODERATE 
 3 = SEVERE 
 4 = VERY SEVERE 
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Page 6 - Question 27 - Open Ended - Comments Box  
Please specify any other symptom(s) that you have difficulty with and rate on the 1-4 scale as in previous 
questions 
 
 
 
 
 
Page 7 - Question 28 - Rating Scale - Matrix [Mandatory] 
Do you have any trouble doing strenuous      activities, like carrying a heavy shopping bag or a  suitcase? 
N o t  a t  a l l A  l i t t l e Q u i t e  a  b i t V e r y  m u c h 
  1  2  3  4
 
Page 7 - Question 29 - Rating Scale - Matrix [Mandatory] 
Do you have any trouble taking a long walk? 
N o t  a t  a l l A  l i t t l e Q u i t e  a  b i t V e r y  m u c h 
  1  2  3  4
 
Page 7 - Question 30 - Rating Scale - Matrix [Mandatory] 
Do you have any trouble taking a short walk outside of the house? 
N o t  a t  a l l A  l i t t l e Q u i t e  a  b i t V e r y  m u c h 
  1  2  3  4
 
Page 7 - Question 31 - Rating Scale - Matrix [Mandatory] 
Do you need to stay in bed or a chair during the day? 
N o t  a t  a l l A  l i t t l e Q u i t e  a  b i t V e r y  m u c h 
  1  2  3  4
 
Page 7 - Question 32 - Rating Scale - Matrix [Mandatory] 
Do you need help with eating, dressing, washing yourself or using the toilet? 
N o t  a t  a l l A  l i t t l e Q u i t e  a  b i t V e r y  m u c h 
  1  2  3  4
 
Page 8 - Heading  
The next 6 questions are about your quality of life 
Description 
 
Page 8 - Question 33 - Rating Scale - Matrix [Mandatory] 
How would you describe your overall Quality of Life? 
As bad as it can be         As good as it can be  
  1  2  3  4  5  6  7  8  9  1 0
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Page 8 - Question 34 - Rating Scale - Matrix [Mandatory] 
Your overall mental (intellectual) well-being? 
As bad as it can be l a b e l l a b e l l a b e l L a b e l l a b e l l a b e l l a b e l l a b e l As good as it can be  
  1  2  3  4  5  6  7  8  9  1 0
 
Page 8 - Question 35 - Rating Scale - Matrix [Mandatory] 
Your overall physical well being? 
As bad as it can be l a b e l l a b e l l a b e l L a b e l l a b e l l a b e l l a b e l l a b e l As good as it can be  
  1  2  3  4  5  6  7  8  9  1 0
 
Page 8 - Question 36 - Rating Scale - Matrix [Mandatory] 
Your overall emotional well-being? 
As bad as it can be l a b e l l a b e l l a b e l L a b e l l a b e l l a b e l l a b e l l a b e l As good as it can be  
  1  2  3  4  5  6  7  8  9  1 0
 
Page 8 - Question 37 - Rating Scale - Matrix [Mandatory] 
Your level of social activity? 
As bad as it can be l a b e l l a b e l l a b e l L a b e l l a b e l l a b e l l a b e l l a b e l As good as it can be  
  1  2  3  4  5  6  7  8  9  1 0
 
Page 8 - Question 38 - Rating Scale - Matrix [Mandatory] 
Your overall spiritual well-being? 
As bad as it can be l a b e l l a b e l l a b e l L a b e l l a b e l l a b e l l a b e l l a b e l As good as it can be  
  1  2  3  4  5  6  7  8  9  1 0
 
Page 9 - Heading  
Providing some additional personal information as accurately as you can will help us learn more about 
caring for cancer patients. We appreciate you sharing and will hold the information in the strictest 
confidence. 
Description 
 
Page 9 - Question 39 - Choice - One Answer (Bullets) [Mandatory] 
What age range do you fall into? 
 
 18-30 
 31-40 
 41-50 
 51-60 
 61-70 
 71+ 
 
Page 9 - Question 40 - Choice - One Answer (Bullets) [Mandatory] 
With which of the ethnic/racial group do you principally identify? 
 
 White 
 Black 
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 Asian 
 Hispanic 
 Other, please specify 
 
 
Page 9 - Question 41 - Choice - One Answer (Bullets) [Mandatory] 
What is the highest level of formal schooling you have completed? 
 
 Grade school 
 High school 
 Vocational or associate degree 
 Bachelor’s degree 
 Masters or other graduate degree 
 
Page 9 - Question 42 - Choice - Multiple Answers (Bullets) [Mandatory] [Up To 4 Answers] 
Treatment for my breast cancer included (check all that apply) 
 
 Surgery 
 Chemotherapy 
 Radiation therapy 
 Other, please specify 
 
 
Page 9 - Question 43 - Choice - One Answer (Bullets) [Mandatory] 
I completed my treatment 
 
 Within the past 6 months 
 6 months to 1 year 
 1 to 2 years 
 2 to 5 years 
 5 to 10 years 
 10+ years 
 I am still receiving treatment 
 
Page 9 - Question 44 - Choice - Multiple Answers (Bullets) [Mandatory] [Up To 3 Answers] 
Primary caregiver (check all that apply) 
 
 Myself 
 Spouse or partner 
 Other, please specify 
 
 
Page 10 - Question 45 - Choice - Multiple Answers (Bullets) [Mandatory] [Up To 6 Answers] 
Do you have any children living at home (check all that apply)? 
 
 No children at home 
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 Under 6 years old 
 7-17 years of age 
 18-26 years of age 
 Older than 26 years old 
 Please specify number of children in each age range selected 
 
 
Page 10 - Question 46 - Choice - One Answer (Bullets) [Mandatory] 
Do you have any conditions (other than being a breast cancer survivor) that could cause symptoms? 
 
 No 
 Yes 
 If yes, please specify 
 
 
Page 10 - Question 47 - Choice - One Answer (Bullets) [Mandatory] 
Are you currently taking any medications? (Over-the-counter, Herbals, Prescription, etc.) 
 
 No 
 Yes 
 If yes, please specify 
 
 
Page 10 - Question 48 - Choice - One Answer (Bullets) [Mandatory] 
In order to get better information about symptoms some individuals who complete this survey will be 
selected to participate in an additional aspect of the study. This will involve answering a questionnaire 
and providing a saliva sample. Including travel, this would take 2-3 additional hours of your time.  I would 
like to be contacted to participate in additional aspects of this study. 
 
 Yes (please provide contact information in the fields below) 
 No 
 
Page 10 - Question 49 - Name and Address (U.S)  
If you are willing to be contacted please fill out the information below accurately and completely. 
 
 Name 
 Phone number 
 Address 1 
 Address 2 
 City 
 State 
 Zip 
 Email Address 
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Page 10 - Question 50 - Open Ended - Comments Box  
Please share any other information that you feel would be important if you were to be included in further 
study about symptoms: (for example--location, date, time, and give your preferences for these or other 
items) 
 
 
 
 
 
 
 
 
 
Thank You Page 
If you have any questions about the survey or additional research that will be conducted, please feel free 
to contact me:<br />Sylvia Heinze<br />302-519-3068<br />sheinze@kumc.edu 
 
Screen Out Page 
Thank you for your interest in participation but the study requires a different profile. 
 
Over Quota Page 
Standard 
 
Survey Closed Page 
Standard 
 
 
 
 
 
 
 
 
 
 
Thank you for participating in this survey! 
If you have any questions about the survey or additional research that will be conducted, please feel free to contact 
me: 
Sylvia Heinze 
302-519-3068 
sheinze@kumc.edu 
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Appendix D 
 
Therapy-Related Symptom Checklist (TRSC) 
 
PLEASE CHECK THE PROBLEMS YOU HAVE HAD THAT YOU BELIEVE ARE RELATED TO 
YOUR CANCER OR TREATMENT. PLEASE CIRCLE HOW SEVERE THE PROBLEM WAS 
ACCORDING TO THE FOLLOWING SCALE: 
  
0 = NONE 1 = MILD 2 = MODERATE 3 = SEVERE 4 = VERY SEVERE 
 
CHECK EXAMPLE Degree of Severity (CIRCLE) 
 Pain 
 
0 1 2  4 
  Taste Change 0 1 2 3 4 
  Loss of appetite 0 1 2 3 4 
  Nausea 0 1 2 3 4 
  Vomiting 0 1 2 3 4 
  Weight loss 0 1 2 3 4 
  Sore mouth 0 1 2 3 4 
  Cough 0 1 2 3 4 
  Sore throat 0 1 2 3 4 
  Difficulty swallowing 0 1 2 3 4 
  Jaw pain 0 1 2 3 4 
  Shortness of breath 0 1 2 3 4 
  Numbness in fingers and/or toes 0 1 2 3 4 
  Feeling sluggish 0 1 2 3 4 
  Depression 0 1 2 3 4 
  Difficulty concentrating 0 1 2 3 4 
  Fever 0 1 2 3 4 
  Bruising 0 1 2 3 4 
  Bleeding 0 1 2 3 4 
  Hair loss 0 1 2 3 4 
  Skin changes 0 1 2 3 4 
  Soreness in vein where chemotherapy was given 0 1 2 3 4 
  Difficulty sleeping 0 1 2 3 4 
  Pain 0 1 2 3 4 
  Decreased interest in sexual activity 0 1 2 3 4 
  Constipation 0 1 2 3 4 
  Other problems (please list below)      
 ______________________ 0 1 2 3 4 
 ______________________ 0 1 2 3 4 
 ______________________ 0 1 2 3 4 
 ______________________ 0 1 2 3 4 
Phoebe D. Williams, PhD ©Copyright 1995 University of Kansas Medical Center   
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Appendix E 
 
Daily Activities Rating Scale 
 
 We are interested in some things about you and your health. Please answer all of the questions 
yourself by choosing the number that best applies to you. There are no “right” or “wrong” answers. 
The information that you provide will remain strictly confidential. 
 
 Not at 
all 
A little Quite a 
bit 
Very 
much 
 Do you have any trouble doing strenuous      
 activities, like carrying a heavy shopping bag or a  
 suitcase? 
 
 
 
1 2 3 4 
 Do you have any trouble taking a long walk? 
 
 
 
 
1 2 3 4 
 Do you have any trouble taking a short walk  
 outside of the house? 
 
 
 
1 2 3 4 
 Do you need to stay in bed or a chair during the  
 day? 
 
 
 
1 2 3 4 
 Do you need help with eating, dressing, washing   
 yourself or using the toilet? 
 
 
 
 
 
 
1 2 3 4 
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Appendix F 
Health-Related Quality of Life (HRQOL)-Linear Analogue Self Assessment (LASA) 
 
Patient Name: __________________________ Date: _______________ ID Number: ________________ 
 
Directions: Please circle the number (0-10) best reflecting your response to the following that describes 
your feelings during the past week, including today. 
 
A.  How would you describe: 
 
1.  Your overall Quality of Life? 
 
 0 1 2 3 4 5 6 7 8 9 10   
 As bad as it can be                 As good as it can be  
 
2. Your overall mental (intellectual) well-being? 
 
 0 1 2 3 4 5 6 7 8 9 10   
 As bad as it can be      As good as it can be 
 
3. Your overall physical well-being? 
 
 0 1 2 3 4 5 6 7 8 9 10   
 As bad as it can be       As good as it can be  
 
4. Your overall emotional well-being? 
 
 0 1 2 3 4 5 6 7 8 9 10   
 As bad as it can be       As good as it can be  
 
5. Your level of social activity? 
 
 0 1 2 3 4 5 6 7 8 9 10   
 As bad as it can be       As good as it can be  
 
6. Your overall spiritual well-being? 
 
0 1 2 3 4 5 6 7 8 9 10   
 As bad as it can be      As good as it can be  
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Appendix G 
Symptom Alleviation: Self-Care Methods (SA: SCM) Tool 
 
ID# ______________Date: ____________ 
Name: _________________________ Data Collector: __________________________________________ 
_______________________________________________________________________________ 
 
 
 
 
 
 
ALLEVIATION METHODS DONE OR 
USED (Please list below) 
 
*How often Done? 
 4, Very Often Done; 
3, Often Done; 
2, Done Occasionally; 
1, Seldom Done; 
0, Not Done
 
Did 
it 
Help? 
 
 (Yes/No)
 
 
 
 
 Taste Change 
 
   
 Loss of appetite 
 
   
 Nausea 
 
   
 Vomiting 
 
   
 Weight loss 
 
   
 Sore mouth 
 
   
 Cough 
 
   
 Sore throat 
 
   
 Difficulty swallowing 
 
   
 Jaw pain 
 
   
 Shortness of breath 
 
   
 Numbness in fingers    
and/or toes 
   
 Feeling sluggish 
 
   
 Depression 
 
   
 Difficulty  
concentrating 
   
 Fever 
 
   
 Bruising 
 
   
 Bleeding    
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 Hair loss 
 
   
 Skin changes 
 
   
 Soreness in vein                
where chemotherapy 
given 
   
 Difficulty sleeping 
 
   
 Pain 
 
   
 Decreased interest in 
sexual activity 
   
 Constipation 
 
   
 Other problems  
(please list below) 
   
    
    
    
    
    
*Rate each alleviation method used—then, each reported symptom would have a mean alleviation 
rating  
Copyright© 2009 Phoebe D. Williams, PhD 
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Appendix H 
Informed Consent Form 
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Appendix I 
 
Oragene DNA Self-Collection Kit User Instructions 
 
 
Oragene®•DNA Self-Collection Kit User 
Instructions  
(OG-500 Tube Format) 
Do not eat, drink, smoke or chew gum for 30 minutes before giving your 
saliva sample. 
 
  
    
 
Spit until the 
amount of 
saliva (not 
bubbles) 
reaches the 
fill line. 
 
 
Close lid by 
pushing down 
hard on the 
funnel lid. 
 
 
Unscrew the 
tube from the 
funnel. 
 
 
Close tube 
tightly with 
small cap and 
mix. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
